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Cancer treatment is moving towards precision medicine based on therapy that is tailored to 
patient and tumor characteristics. The current clinicopathological risk assessment methods 
of endometrial carcinoma (EC) are not optimal and both under- and overtreatment occur. 
To provide more objective tools for personalized treatment, research efforts focus on the 
molecular landscape of EC. A landmark study by the Cancer Genome Atlas (TCGA) research 
group defined a novel histotype-independent classification of EC based completely on 
molecular features.  
This thesis consists of five retrospective studies that were conducted to investigate the 
relevance of various molecular biomarkers in EC. Emphasis was placed on L1 cell adhesion 
molecule (L1CAM), a promising and relatively novel prognostic factor of EC. In addition, we 
examined the clinicopathological significance of MLH1 methylation status in mismatch 
repair deficient (MMRd) EC. Further, we profiled the expression of an immunotherapy target 
molecule, programmed death ligand 1 (PD-L1), within histological and molecular subgroups 
of EC. Lastly, we investigated the differential impact of individual risk factors across the two 
largest TCGA-based molecular subgroups of EC. The studies were based on a cohort of 842 
patients who were surgically treated for EC at the Department of Obstetrics and Gynecology, 
Helsinki University Hospital, between January 2007 and December 2012. 
In the first study, including 805 patients, we examined the prognostic significance of L1CAM 
in the postoperative setting of EC. L1CAM positivity determined by immunohistochemistry 
was associated with several poor clinicopathological prognostic factors. In addition, L1CAM 
expression was associated with more frequent distant (extra-abdominal) relapses and poor 
prognosis in the subgroup of endometrioid EC but not in non-endometrioid EC.  
The second study investigated the value of L1CAM in preoperative risk stratification. 
Immunohistochemistry for L1CAM was conducted on endometrial biopsies of 241 EC 
patients. Preoperative tumoral L1CAM positivity was associated with poor prognostic 
features including lymph node involvement/advanced stage. However, integrating L1CAM 
with the conventional risk assessment models did not improve the capability of predicting 
nodal dissemination or distant metastases.  
In the third study, multiplex fluorescent immunohistochemistry-based PD-L1 scorings were 
performed on 804 EC samples. PD-L1 expression was more frequent in intratumoral immune 
cells (27.7%) than in carcinoma cells (8.6%). With the combined positive score (CPS) method, 
19.4% of the samples were positive for PD-L1. Within the molecular subgroups, POLE-




positivity, and PD-L1 expression in immune cells than the other molecular groups (p53 
abnormal and no specific molecular profile, NSMP). Non-endometrioid carcinomas and  
advanced stage tumors were more likely to display PD-L1 positivity than endometrioid 
carcinomas and early-stage tumors, respectively. Finally, we performed concordance 
analysis between multiplex and conventional chromogenic immunohistochemistry, where 
CPS outperformed the scoring systems based on a single cell type (carcinoma cells or 
immune cells).  
In the fourth study, we classified 682 endometrioid ECs on the basis of MMR protein 
expression and MLH1 promoter methylation status. MMR immunohistochemistry identified 
35.8% of the cases as MMR-deficient and the majority (76%) of these were linked to MLH1 
methylation. MMR deficiency correlated with several negative clinicopathological 
prognostic factors. Methylated phenotype was associated with older age and larger tumor 
size. Methylated MMRd phenotype predicted poor disease-specific survival compared with 
MMR-proficient EC, but the difference with non-methylated MMRd EC was not significant. 
We found no association between methylation status and quantity of intratumoral T-cells or 
PD-L1 expression.  
In the fifth study, TCGA-based molecular classification was performed for 535 cases of 
endometrioid EC. The original TCGA survival curves were reproduced with POLE mutated EC 
having an excellent prognosis, followed by NSMP, MMRd, and the more aggressive p53 
abnormal EC. In multivariable analysis, survival difference between NSMP and MMRd groups 
became non-significant after adjusting for principal clinicopathological risk factors, 
suggesting that the negative prognostic effect of MMRd reflects the more frequent presence 
of conventional risk factors in this subgroup. Survival analyses were also performed 
separately for the two largest molecular subgroups, MMRd (n=264) and NSMP (n=206), in 
order to identify subgroup differences in the prognostic effect of single clinicopathological 
and molecular risk factors. Interaction analysis confirmed a significantly stronger impact of 
high grade (G3) and p16 hyperexpression in the NSMP group than in the MMRd group.  
This thesis identifies molecular markers that may improve clinical management of EC 
patients. We confirmed the value of L1CAM as a postoperative prognostic marker in the 
endometrioid subtype of EC. By contrast, our results do not support integrating L1CAM into 
current lymphadenectomy stratification algorithms, as this offers no advantages relative to 
conventional methods. If TCGA-based molecular classifiers were to be introduced in the 
preoperative treatment algorithms, the role of L1CAM might need to be re-evaluated within 
this context. We demonstrated the clinicopathological significance of methylation profiling 
in MMRd EC. Differences in the impact of risk factors and in PD-L1 expression within TCGA 
subgroups supports the adoption of a molecular subgroup-specific study approach when 
formulating treatment algorithms for patients with EC.  





AI aromatase inhibitor 
AUC  area under curve 
BMI body mass index 
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CPS combined positive score 
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ER estrogen receptor 
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HR hazard ratio 
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LVSI lymphovascular space invasion 
MMR mismatch repair 
MMRd mismatch repair deficient 
MRI magnetic resonance imaging 
MSI microsatellite instability 
NSMP no specific molecular profile 
p53abn p53 abnormal 
PD-L1 programmed death ligand 1 
POLE polymerase epsilon 
      PR progesterone receptor 
TCGA The Cancer Genome Atlas 
TMA tissue microarray 
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Endometrial carcinoma (EC) is a pathogenetically and prognostically heterogeneous group 
of diseases. Early-stage EC generally carries an excellent prognosis and may be cured by 
surgery alone. Total hysterectomy and bilateral salpingo-oophorectomy form the 
cornerstone of the treatment. Patients with a significant risk of disseminated disease also 
undergo pelvic and para-aortic lymphadenectomy and may receive adjuvant chemo- and/or 
radiotherapy. Recently, immunotherapy has emerged as an ancillary treatment option for 
cancer patients, but the indications are not fully established for EC.  
Preoperative risk assessment stratifies EC patients with regard to lymph node dissection. 
Whether lymphadenectomy itself offers therapeutic effects is unclear, but foremost it serves 
staging purposes [1, 2]. Postoperative risk stratification based on clinicopathological 
parameters including nodal status, guides the selection of adjuvant therapy. Extensive 
surgery and adjuvant therapies entail complications and not all patients benefit from them 
[3, 4]. Current risk stratification methods have limitations in identifying patients requiring 
intensive treatment. Approximately 10% of patients with a preoperatively determined low-
risk EC shift to the high-risk category after the final pathological evaluation, indicating a risk 
of incomplete surgical staging and under-treatment [5]. On the other hand, 80% of patients 
subjected to lymphadenectomy eventually present with no nodal dissemination [6]. In the 
postoperative setting, up to 10% of patients with a presumably low or intermediate-risk 
disease experience recurrence [7].  
Molecular classifiers of EC offer more objective tools for risk stratification. In 2013, The 
Cancer Genome Atlas (TCGA) consortium identified four prognostically and pathogenetically 
distinct subgroups of EC: POLE ultramutated, microsatellite instability (MSI) hypermutated, 
copy-number low, and copy-number high [8]. How these molecular subclasses and other risk 
factors should be integrated in the EC risk assessment algorithms and whether the four 
molecular subgroups should be treated as separate disease entities remain to be 
established. This thesis explores various prognostic and predictive factors of EC and 
investigates their relevance within the TCGA-based molecular subgroups.
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EPIDEMIOLOGY
Cancer of the uterine corpus is the fourth most common cancer in females in the Western 
world [9]. Lifetime risk of EC is approximately 3% and this malignancy accounts for 4% of all 
cancer deaths in women [9]. The vast majority (95%) of uterine cancers are endometrial 
carcinomas, i.e. they develop in the epithelial compartment of the uterine mucosa 
(endometrium). The remaining 5% include sarcomas and other rare malignancies.  
The median age at EC diagnosis is 62 years [10]. Approximately 20–25% of endometrial 
carcinomas occur in premenopausal patients and 5% occur in patients younger than 40 years 
[11]. Most women are diagnosed at an early stage i.e. before the cancer has spread outside 
the uterus, when the disease carries a good prognosis [12]. The 5-year relative survival rate 
of all EC patients is approximately 80% (Finnish Cancer Registry 2017).  
RISK FACTORS
Many of the known risk factors of EC are related to unopposed estrogen exposure. The 
effects of hyperestrogenism and/or progesterone deficiency reflect the proliferative and 
growth suppressive responses that estrogen and progesterone physiologically exert on the 
endometrium.  
The increased risk of EC associated with reproductive factors, such as nulliparity, early 
menarche, and late menopause, supports the relationship between cancer risk and greater 
premenopausal exposure to estrogens [13]. Other hormone-related risk factors are obesity, 
polycystic ovary syndrome, and diabetes, which also share various metabolic disturbances 
(hyperinsulinemia, insulin resistance, ovarian hyperandrogenism) [14, 15]. Obesity is 
associated with higher levels of circulating estrogens in postmenopausal women and with 
lower progesterone levels in premenopausal women [14]. The hyperestrogenic state related 
to obesity is mainly produced by increased extraovarian aromatization of androgens to 
estrogens occurring in the adipose tissue. Chronic anovulatory cycles resulting from any 
endocrine disorder (including obesity and polycystic ovary syndrome) cause prolonged 
progesterone deficiency and unopposed estrogen exposure. Rarely, hyperestrogenism may 
be caused by estrogen-producing tumors (mainly granulosa cell tumor of the ovary). 
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As for exogenous steroidal hormones, large population-based studies and meta-analyses 
provide evidence that oral contraceptive therapy containing estrogen and progestin reduces 
the risk of EC [16–18]. The contraceptive use of a hormone-releasing intrauterine device also 
appears to be associated with a decreased risk of EC [19, 20]. Menopausal hormone 
replacement therapy based on unopposed estrogen is associated with an increased 
incidence of EC, but the effect of combined hormone replacement therapy is less clear [21].  
Selective estrogen receptor modulators (e.g. tamoxifen) used to treat breast cancer 
patients, increase the risk of uterine pathology (polyps, hyperplasia, carcinoma) [22].  EC risk 
of breast cancer patients is estimated to increase by 2- to 7-fold in tamoxifen users as 
compared to non-users [22]. As a result of the differential recruitment of co-regulators, 
tamoxifen exerts estrogen receptor (ER) antagonistic effects in breast cancer tissue and 
partial ER agonist effects in the endometrium [23]. In addition, several potential ER-
independent carcinogenetic mechanisms of tamoxifen have been described [23]. Aromatase 
inhibitor (AI) -based endocrine treatment of breast cancer appears to be associated with a 
significantly lower risk of EC than tamoxifen treatment. AIs may even reduce the risk of EC 
compared with patients not receiving endocrine treatment [24]. At a hypothetical level, a 
protective effect of AIs can be expected, given their inhibitory action on estrogen 
production. As ovarian production of estrogen is not effectively inhibited by AIs, their use is 
recommended mainly for postmenopausal patients [25]. 
As regards non-steroidal hormones, hyperinsulinemia is the best-known risk factor for EC. A 
meta-analysis including 16 studies reported an approximately twofold risk of EC for diabetic 
compared with non-diabetic patients [15]. Studies included in the meta-analysis were mainly 
conducted on patients with type II diabetes, but similar results were found in studies 
restricted to type I diabetes [15]. The association remained significant after controlling for 
body mass index suggesting a body weight-independent effect. Insulin is a known growth 
factor, that among many target organs, promotes proliferation in endometrial cells. The 
effect is both direct via insulin signaling and indirect via regulation of the synthesis of various 
other proteins.  For instance, insulin inhibits the synthesis of insulin-like growth factor (IGF) 
binding proteins, thereby increasing the level of free circulating IGF-1, a molecule which also 
has a proliferative effect on endometrial cells. In addition, insulin influences the levels of sex 
hormones by stimulating androgen synthesis in the ovary and adrenal gland, by enhancing 
aromatase production in endometrial stroma and by inhibiting the synthesis of circulating 
sex hormone binding globulin (SHBG) [26, 27]. Androgens are an estrogen reservoir, and 
therefore, an EC risk factor, but whether they have a direct cancerogenic effect is less clear 
[26, 28].  
Approximately 3–5% of cases of uterine cancer are attributable to a hereditary cause [29–
31]. The most common cause of familial EC is Lynch syndrome (formerly hereditary 
nonpolyposis colorectal cancer). Lynch syndrome is an autosomal dominant cancer 
predisposition syndrome, caused by deleterious germline mutation of a DNA mismatch 
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repair (MMR) gene (MLH1, PMS2, MSH2, MSH6) or germline deletion of the adjacent 
epithelial cell adhesion molecule gene (EPCAM), which leads to constitutive inactivation by 
methylation of MSH2. In addition, rare cases of hereditary (constitutive) hypermethylation 
of MLH1 have been reported [32]. EC is the most common extracolonic manifestation of the 
syndrome with a lifetime risk of 40–60% in female Lynch syndrome patients [33]. Cowden 
syndrome is a rare autosomal dominant disorder caused by mutations in the phosphatase 
and tensin (PTEN) tumor suppressor gene. Lifetime risk of EC in female patients with Cowden 
syndrome is 5–10% [34].  
 
PRECURSOR LESIONS OF ENDOMETRIAL CARCINOMA 
  
Carcinogenesis is a multistep process in which cells accumulate genetic and epigenetic 
alterations inducing uncontrolled cell proliferation and impaired DNA repair functions, 
leading to further accumulation of genetic changes. The 2020 World Health Organization 
(WHO) classification categorizes two histological precursor lesions for EC: endometrial 
hyperplasia without atypia and atypical hyperplasia/endometrioid intraepithelial neoplasia 
[35]. Histologically, hyperplastic endometrium is characterized by exaggerated growth of 
irregular glands with an increase in the gland-to-stroma ratio compared with normal 
proliferative endometrium.  
Many of the genetic alterations described in carcinoma have been reported in co-existing 
endometrial hyperplasia. Generally, the number of coexisting alterations increases from 
hyperplastic lesions to carcinoma supporting the theory of multistep tumorigenesis 
progressing through precursor lesions [36–40]. Rate of progression to carcinoma is 1–3% for 
non-atypical hyperplasia and 25–33% for atypical hyperplasia. Hyperplasia frequently 
develops in the setting of long-lasting unopposed estrogen exposure and is considered a risk 
factor for Bokhman’s type I EC (see Histological classification and molecular background 
below). On the contrary, serous endometrial intraepithelial carcinoma, given its metastatic 
potential, is not considered a precursor lesion by the WHO 2020 classification, but rather a 
non-invasive form of carcinoma [35]. 
 
HISTOLOGICAL CLASSIFICATION AND MOLECULAR BACKGROUND 
In 1983, Bokhman introduced a dualistic model of pathogenetic types of EC based on clinical 
observations and histopathological characteristics, but not molecular features [41]. "Type I" 
cancers (65%) were mostly represented by low-grade (G1-2) endometrioid tumors arising in 
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pre- or perimenopausal women, who often present hyperestrogenism, obesity, and other 
signs of metabolic syndrome. Typically, these carcinomas follow a favorable course (85.6% 
5-year survival rate). "Type II" cancers (35%) follow an estrogen-unrelated pathway and 
generally develop from atrophic endometrium in postmenopausal women in the absence of  
signs of endocrine and metabolic disturbances stated above. Type II cancers are typically 
high-grade carcinomas (G3 endometrioid or non-endometrioid EC). These tumors follow an 
aggressive clinical course (58.8% 5-year survival rate) [41].  
Type I and type II ECs present divergent molecular features. However, tumors with 
overlapping features exist, and the dualistic classification of Bokhman has been challenged. 
The most common genetic alteration in type I EC (40–60%) is inactivation of PTEN [37, 42, 
43]. PTEN acts as a major antagonist of the PI3K–AKT pathway that controls cell proliferation 
and cell survival. Activating mutations of PIK3CA, which is part of the same pathway, are also 
common (20–40%) [39, 44]. Loss of ARID1A (AT-rich interacting domain-containing protein 
1A), a member of a chromatin remodeling complex that regulates transcription, occurs in 
approximately 30% of endometrioid ECs [45, 46]. Approximately one-third (25–40%) of 
endometrioid carcinomas present an impaired DNA MMR system caused by a loss of 
function of one of the MMR genes (MLH1, PMS2, MSH2, MSH6).  MSI represents phenotypic 
evidence of an impaired MMR system. In the majority of cases, MMR gene silencing is a 
sporadic event due to somatic MLH1 promoter hypermethylation [47, 48]. In approximately 
half of the remaining cases, i.e. Lynch syndrome suspected cases, a germline mutation can 
be confirmed [49]. Some of the methylation-negative and germ line-negative (Lynch-like) 
cases have been shown to harbor biallelic somatic mutations [50–52]. Mutation-induced 
constitutive KRAS activity leading to uncontrolled cell proliferation is found in 18–28 % of 
endometrioid EC. Alterations in PTEN, PIK3CA, KRAS, MMR genes and ARID1a frequently co-
exist, whereas an equally frequent (20–40%), but apparently independent, mutational 
process involves beta-catenin gene (CTNNB1) [8, 44, 53–55]. Beta-catenin is a component of 
the E-cadherin–catenin unit, and mutations of CTNNB1 result in aberrant nuclear 
accumulation of the protein leading to transcriptional activation.  
The above molecular aberrations are rare in type II EC, where the most common genetic 
alteration involves TP53 gene (90 % of serous carcinomas). P53 is a tumor suppressor protein 
that blocks cell proliferation and promotes apoptosis when DNA damage occurs in the cell. 
Cells with inactivated TP53 suffer from genetic instability at the chromosome level resulting 
in aneuploidy and numerous copy number changes. Other molecular changes often present 
in serous carcinomas are altered expression of the cell cycle regulatory gene p16, 
amplification of Her2/neu oncogene (40–80%, member of the human epidermal growth 
factor receptor family) and mutations of E-cadherin leading to loss of the homonymous 
structural protein (60–90%) [56]. High-grade (G3) endometrioid carcinomas often share 
molecular features with serous carcinomas. Most importantly, they present TP53 mutations 
and p16 overexpression relatively frequently (37.5–61.0% and 11.0–30.4%, respectively) 
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[57–59]. In contrast to serous ECs, they rarely show Her-2 amplification [57]. Endometrial 
clear cell carcinoma, which is considered an uncommon type II carcinoma, shares common 
molecular changes with endometrioid carcinomas, including loss of PTEN, MMR proteins, 
and ARID1A, but also exhibits alterations in the expression of TP53 and p16 [60].  
The 2020 WHO classification of tumors of the uterine corpus defines several distinct 
histological subtypes of EC: endometrioid (≈70%), serous (10%), clear cell (<10%), mixed cell 
adenocarcinoma (10%, diagnosed and graded as high-grade carcinoma irrespective of the 
relative proportion of serous or clear cell carcinoma present), carcinosarcoma (5%), and 
undifferentiated and dedifferentiated carcinoma (2%). Very rare histotypes include 
squamous cell carcinoma, high-grade neuroendocrine carcinoma, low grade 
neuroendocrine tumor, mucinous carcinoma (intestinal type), and mesonephric and 
mesonephric-like adenocarcinoma [35]. Histotypes are distinguished based on tumor 
architecture, cell morphology and nuclear features. Endometrioid carcinoma presents 
histological features most closely resembling normal proliferative endometrium and 
frequent squamous differentiation. Various histological patterns (e.g. secretory, 
microglandular, mucinous, and spindle cell patterns) are recognized in the classification, but 
they do not carry prognostic information. Endometrioid ECs are graded according to a 
grading system developed by the International Federation of Gynecology and Obstetrics 
(FIGO), which is based on the proportion of non-squamous/non-morular solid tumor (≤5%, 
6–50%, >50%, respectively, for G1, G2, G3). The architectural grade is upgraded by one if 
there is severe nuclear atypia, which should not be associated with features of serous 
carcinoma (marked nuclear pleomorphism, prominent nucleoli, high nuclear-to-cytoplasm 
ratio, frayed luminal border, and frequent mitotic figures that are often abnormal). Binary 
grading classifying G1–2 as low grade and G3 as high grade is recommended [35]. Histology-
based classification of EC suffers from poor reproducibility, especially in the diagnosis of 






Figure 1. Representative images of endometrial carcinoma histotypes: a) G1 
endometrioid carcinoma, b) serous carcinoma, c) clear cell carcinoma. 
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TCGA MOLECULAR CLASSIFICATION OF ENDOMETRIAL 
CARCINOMA 
TCGA consortium performed genomic, transcriptomic, and proteomic characterization of 
373 ECs and identified four prognostically distinct molecular subgroups: POLE ultramutated 
(7% of cases), MSI hypermutated (28%), copy-number low (39%), and copy-number high 
(26%) tumors (Figure 2) [8].   
 
The analyses of tumor mutational burden and somatic copy number alterations require 
methodologies that are laborious, expensive, and unsuitable for clinical application. 
Subsequently, two research groups replicated the TCGA survival curves with classifiers based 
on more pragmatic surrogate markers, i.e. the “Leiden classification” by the PORTEC group 
and the “Proactive Molecular Risk Classifier for Endometrial Cancer” (ProMisE) by the 
Vancouver group. These molecular classifiers are based on targeted POLE exonuclease 
domain mutational analysis as a surrogate for ultramutated EC, MMR markers for the 
hypermutated subgroup and p53 aberration for the copy-number high subgroup. In the 
Leiden model, MMR status is assessed by MSI analysis validated by MMR 
immunohistochemistry (IHC). P53 status is defined by IHC, followed by TP53 mutational 
testing in indeterminate cases [62].  The ProMisE model is based on MMR protein and p53 
IHC [63]. Tumors not presenting any of the above alterations are classified as no specific 
molecular profile/p53 wild type (NSMP/p53wt), a surrogate for the copy-number low group. 
In the original TCGA model and in ProMisE, tumors are classified in a stepwise fashion. The 
major difference between these proposed decision trees lies in the order in which tumors 
are subcategorized. In the original TCGA algorithm, the first step of the decision tree 
separates the POLE ultramutated subgroup. POLE wild type tumors are further categorized 
Figure 2. TCGA survival curves for 
EC (Cancer Genome Atlas, 2013) 
With permission from Nature. 
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according to the MSI status and microsatellite stable tumors according to copy number 
alterations. In the ProMisE model, the first subgroup assignment is based on the MMR status 
(Figure 3). Tumors with intact MMR proteins undergo POLE mutational analysis, and POLEwt 
tumors are classified as p53 abnormal (p53abn) or p53wt. In the Leiden algorithm, all 
molecular markers are determined for each sample, and cases with multiple molecular 
alterations are discarded from the classification. By contrast, in the original TCGA 
classification and in the ProMisE classification, tumors may present multiple molecular 
alterations, although this occurs rarely.  
 
Main characteristics of the TCGA/Leiden/ProMisE subclasses: 
 
 
POLE ultramutated/POLE mutant/POLE exonuclease domain mutated 
endometrial carcinoma 
DNA polymerase ε exonuclease domain recognizes and removes mispaired nucleotides 
during DNA replication and deleterious mutation of POLE leads to ultrahigh mutational rates 
(232×10−6 mutations/Mb) [8, 63]. POLE mutated (POLEmut) ECs relatively frequently (40%) 
have high-grade (G3) endometrioid morphology [64]. Regardless of the high mutational 
frequency and the high grade of differentiation, POLEmut EC appears to have an excellent 
prognosis [8, 62, 63]. It is not known whether the good prognosis reflects an intrinsic quality 
of the disease or an increased sensitivity to adjuvant treatment [65, 66].  
 
Figure 3. ProMisE molecular classification of endometrial carcinoma. Talhouk et al. 
(2016). With permission from Gynecol Oncol Res Pract.  
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MSI hypermutated/MSI/MMR-deficient endometrial carcinoma
An impaired mismatch repair system leads to genomic instability and high mutational rates 
(18×10−6 mutations/Mb). Microsatellite unstable ECs generally exhibit favorable 
endometrioid histotype but are also associated with negative prognostic factors, including 
advanced stage, high grade of differentiation, lymphovascular space invasion (LVSI), and 
myometrial invasion [67–70].  
Studies on colorectal cancer have provided evidence that MSI phenotype predicts resistance 
to 5-fluorouracil chemotherapy [71, 72]. By contrast, MSI/MMRd phenotype is associated 
with good response to immune check-point inhibitor treatment in many cancer types 
including EC [73–76]. In EC, MMR status may also correlate with response to adjuvant 
radiotherapy [77, 78].  
Along with prognostic and predictive implications, MSI/MMR analysis is a useful screening 
test for Lynch syndrome. PCR-based MSI analysis and MMR IHC can be used to determine 
MMR deficiency. When loss of MLH1 is observed by IHC, methylation analysis may be 
conducted to exclude patients with a methylation-linked (presumably sporadic) disease 
from genetic counseling and germline mutation analysis. Limited data have been published 
regarding clinicopathologic differences between sporadic and hereditary or methylated and 
non-methylated MMRd ECs. 
 
Copy-number low/No specific molecular profile, NSMP/p53wt endometrial 
carcinoma
Copy-number low tumors are mainly low-grade endometrioid carcinomas with a relatively 
low mutational frequency (2.9×10−6 mutations/Mb). Characteristically, they present 
frequent (52%) mutations of the β-catenin encoding gene, CTNNB1. Other mutations with 
relatively high frequency are PTEN, PIK3CA, ARID1A, and KRAS [8]. NSMP tumors have an 
intermediate prognosis, similar or somewhat better than that of MSI tumors [8, 63, 79].  
 
Copy-number high/p53 mutant/p53 abnormal endometrial carcinoma
Most serous carcinomas and approximately one fourth of high-grade endometrioid ECs 
cluster into this tumor group that is characterized by extensive somatic copy number 
alterations, frequent TP53 mutations and a relatively low overall mutational rate (2.3x10−6 
mutations/Mb) [8]. P53-mutated phenotype independently predicts poor survival and is 
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associated with the frequent presence of other poor prognostic factors, which further 
aggravate the prognosis [80, 81]. 
 
CURRENT METHODS OF RISK STRATIFICATION AND TREATMENT 
PLANNING FOR ENDOMETRIAL CARCINOMA
Preoperative risk stratification and surgical treatment of endometrial carcinoma
The standard primary treatment of EC consists of total hysterectomy and salpingo-
oophorectomy complemented with pelvic and para-aortic lymphadenectomy in selected 
cases. Individual treatment strategies are tailored according to the estimated risk of 
extrauterine dissemination and the patient’s comorbidities. Preoperative risk stratification 
of EC is based on tumor histology, local extent of the tumor (depth of myometrial invasion 
and cervical stromal invasion) and distant spread, including lymph nodal metastases. Vaginal 
ultrasonography and pelvic magnetic resonance imaging (MRI) are used to estimate the 
depth of myometrial invasion and the presence of cervical stromal invasion; MRI can also be 
used for assessment of regional lymph nodes. Whole-body computed tomography scan is a 
standard method for the detection of distant metastases at many institutions, although its 
cost-effectiveness as a universal preoperative imaging technique remains questionable [3]. 
Preoperative biopsy is taken to determine the histotype (endometrioid vs. non-
endometrioid carcinoma) and grade of differentiation in the case of endometrioid 
carcinoma. Lymphadenectomy may be omitted in patients with a low risk of lymphatic 
dissemination, i.e. patients with G1-2 endometrioid carcinoma with invasion of less than 
one-half of the myometrial thickness [82]. In fact, two randomized trials suggest that 
patients with early-stage EC do not benefit from routine lymphadenectomy, although these 
studies have been challenged [1, 2, 83]. As lymph node status indisputably affects the 
prognosis of EC, lymphadenectomy completes surgical staging. Consequently, a failure to 
recognize a high-risk EC preoperatively leads to omission of lymphadenectomy, incomplete 
surgical staging, and possibly omission of necessary adjuvant treatments.  
To avoid complications of standard pelvic lymphadenectomy (e.g. lymphoedema, 
lymphoceles), sentinel lymph node mapping has been introduced in EC treatment. In a large 
meta-analysis, sentinel node mapping and conventional lymphadenectomy presented 
comparable rates of  detection of metastatic para-aortic nodes and rates of nodal or overall 
recurrence [84]. For the more common pelvic nodal involvement, sentinel lymph node 
assessment may even provide superior detection rates to full lymphadenectomy [84]. This 
may be due to pathological ultrastaging methods applied in sentinel protocols.  




Postoperative risk stratification and adjuvant therapy of endometrial carcinoma
The FIGO staging system for EC changed from clinical to surgical in 1988 and the surgical 




The selection of adjuvant therapy is based on postoperative risk assessment that, in addition 
to FIGO stage, takes into account tumor histology (low-grade endometrioid, high-grade 
endometrioid, non-endometrioid), LVSI, and patient’s age. Risk groups according to the 
consensus conference of the European Society for Medical Oncology (ESMO), European 
Society for Radiotherapy and Oncology (ESTRO), and European Society for Gynecological 
Oncology (ESGO) are depicted in Table 2 [82]. Patients with low (or intermediate) -risk 
disease may forgo adjuvant therapies. Patients with early-stage endometrioid carcinoma 
with uterine risk features (G3, ≥50% myometrial invasion, LVSI) generally receive either 
vaginal brachytherapy or external pelvic radiotherapy. The latter is often preferred when 





Tumor confined to the corpus uteri 
No or less than half myometrial invasion 
Invasion equal to or more than half of the myometrium 





              IIIC1 
             IIIC2 
Local and/or regional spread of the tumor 
Tumor invades the serosa of the corpus uteri and/or adnexae 
Vaginal and/or parametrial involvement 
Metastases to pelvic and/or para-aortic lymph nodes 
Positive pelvic nodes 





Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
Tumor invasion of bladder and/or bowel mucosa 
Distant metastases, including intra-abdominal metastases and/or inguinal 
lymph nodes 
 Table 1. FIGO 2009 staging system for endometrial carcinoma  
Positive cytology is reported separately without changing the stage. Adapted from Pecorelli et 
al. (2009).  
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advanced endometrioid cancer often undergo multimodality treatment with radiation and 
chemotherapy. 
 
Table 2. Risk groups to guide use of adjuvant therapy for EC  
Adapted from ESMO-ESGO-ESTRO guidelines (Colombo et al., 2016). 
 
Immunotherapy in endometrial carcinoma
Immunotherapy stimulates the body’s own immune system to eliminate tumor cells. 
Currently approved forms of immunotherapy mainly involve immune checkpoints, i.e. 
cellular pathways that regulate immunological responses. As an example of physiological 
immune check-point function, cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) 
maintains self-tolerance by blocking potentially autoreactive T-cells from being activated 
[87]. The programmed death 1 (PD-1) pathway is active in early stages of T-cell maturation 
in the thymus and later peripherally, where it attenuates the function of previously activated 
T-cells [87]. In addition to these crucial regulatory molecules, many other pathways 
modulate the amplitude and duration of an immune response. In cancer immunotherapy, 
Risk group Description 
Low Stage I endometrioid, grade 1-2, <50% myometrial invasion, LVSI 
negative 
Intermediate Stage I endometrioid, grade 1-2, ≥50% myometrial invasion, LVSI 
negative 
High-intermediate Stage I endometrioid, grade 3, <50% myometrial invasion, regardless of 
LVSI status 
Stage I endometrioid, grade 1-2, LVSI unequivocally positive, regardless 
of depth of invasion 
High Stage I endometrioid, grade 3, ≥50% myometrial invasion, regardless of 
LVSI status 
Stage II 
Stage III endometrioid, no residual disease 
Non-endometrioid (serous or clear-cell or undifferentiated carcinoma or 
carcinosarcoma) 
Advanced Stage III residual disease and stage IVA 
Metastatic Stage IVB 
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reactivation of silent antitumoral T-cells can be obtained by removing inhibitory signaling 
with immune check-point inhibitors. 
Various phase II studies have reported promising results in EC patients treated with PD-
1/PD-L1 inhibitors [73–76]. A trial including many cancer types (only 1 EC) provided evidence 
that tumors expressing PD-L1 protein more likely benefit from anti-PD1/PD-L1 treatment 
[88]. Various scoring systems exist, and they evaluate PD-L1 expression in carcinoma cells 
and immune cells, separately or in combination [89–91]. Cell type-specific scoring methods 
may suffer from limited reproducibility, as discerning PD-L1-positive carcinoma cells and 
intratumoral immune cells may be difficult [92]. The optimal cut-off for PD-L1 positivity 
needs to be determined specifically for each tumor type. Reported PD-L1 positivity rates in 
EC show wide variation in different studies (0.9-44.3%), presumably due to different 
antibodies used to detect PD-L1 expression and different scoring methods [93-105].  
Tumors with a heavy mutational burden, i.e. POLEmut and MSI ECs, display the highest 
numbers of activated cytotoxic tumor infiltrating lymphocytes, often expressing PD-1 and 
PD-L1 [94, 98, 105, 106].  This “T-cell inflamed PD-L1-positive” phenotype possibly predicts 
favorable response to immunotherapy [107-109]. At present, the Food and Drug 
Administration has approved MMR deficiency and MSI as predictive biomarkers for anti-PD-
1/PD-L1 immune check-point therapy [110]. 
 
INTEGRATING MOLECULAR AND CLINICOPATHOLOGICAL
FACTORS IN RISK ASSESSMENT MODELS
There is evidence that integrated risk models including both molecular and conventional risk 
factors, outperform the current clinicopathological approach [79, 111]. An ongoing 
randomized trial (PORTEC-4a, NCT03469674) is recruiting patients with stage I-II EC and 
compares adjuvant treatment assignments based on standard clinicopathological risk 
factors alone or in combination with molecular risk factors (TCGA markers and L1 cell 
adhesion molecule (L1CAM)). 
L1CAM promotes neuronal migration and differentiation during the development of the 
nervous system. In the cancer microenvironment, it facilitates tumor cell motility, invasion, 
and metastasis [112]. L1CAM has been shown to predict poor prognosis in many cancer 
types [113]. In a large study conducted on stage I endometrioid EC, L1CAM expression ≥10% 
independently predicted poor disease-free and overall survival with impressive hazard ratios 
(HRs, HR=16.33 for recurrence, HR=15.01 for death) even after adjustment for age, grade of 
differentiation, disease stage, and conventional risk group [114]. Further studies 
corroborated the prognostic value of this molecule [115, 116]. Studies including ECs of all 
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stages provide evidence of a correlation between L1CAM expression and advanced stage 
including nodal dissemination of the disease, but the value of L1CAM in preoperative 
stratification to lymphadenectomy is unknown [116, 117].  
In the pre-TCGA era, several other biomarkers, such as ER, PR, ki-67, stathmin, and ASRGL1, 
have been shown to have prognostic value in EC, but large prospective studies 
demonstrating their prognostic utility have not been conducted, and they are currently not 
in clinical use [118-124].
AIMS OF THE STUDY                                                                                                   
     
24 
 
AIMS OF THE STUDY
 
This study was designed to explore the prognostic value of molecular biomarkers and to 
provide data for future EC risk stratification efforts integrating TCGA-based molecular 
subclasses, conventional clinicopathological risk factors and ancillary molecular markers. 
 
Specific objectives were as follows: 
 
I To investigate the prognostic value of L1CAM expression in an unselected EC 
cohort. Specifically, to evaluate the relationship between L1CAM expression, 
relapse patterns, and disease-specific survival separately for endometrioid and 
non-endometrioid EC. 
II  To determine whether preoperative analysis of L1CAM can improve the 
stratification of EC patients to lymphadenectomy. Further, to address the 
correlation between tumoral L1CAM expression and soluble L1 detected in 
serum.  
III  To explore the prevalence of PD-L1 positivity in endometrial carcinoma cells 
and intratumoral immune cells. Further, to demonstrate eventual differences 
in PD-L1 expression profiles across histological and TCGA-based molecular 
subgroups of EC.  
IV  To examine prognostic and clinicopathological differences between 
methylation-linked and non-methylated MMRd ECs. 
V  To evaluate eventual differences in the prognostic impact of known 
clinicopathological risk factors and molecular biomarkers within the two 
largest TCGA-based molecular subgroups (NSMP and MMRd) of EC. 
 
 





PATIENTS AND TUMOR SAMPLES
We used a single-center database to identify all patients who received primary surgical 
treatment for EC at the Department of Obstetrics and Gynecology, Helsinki University 
Hospital between January 2007 and December 2012 (n=965). Formalin-fixed paraffin-
embedded (FFPE) hysterectomy samples of 842 (87.3%) patients were available and suitable 
for the construction of a tumor tissue microarray (TMA). All high-grade endometrioid and 
non-endometrioid cases were reviewed by an experienced gynecopathologist. LVSI was 
defined as the unequivocal presence of tumor cells within an endothelial-lined space outside 
the invasive border. Starting in November 2014, we collected preoperative blood samples 
from voluntary EC patients. The final number of patients, sample types, and methodologies 
of each study are shown in Table 3. The study was approved by the Institutional Review 
Board and National Supervisory Authority for Welfare and Health (Valvira).  
Table 3. Summary of materials and methods in Studies I-V 
IHC=immunohistochemistry, ELISA=enzyme-linked immunosorbent assay, MS-MLPA= 
methylation-specific multiplex ligation-dependent probe amplification 
 
TREATMENT PROTOCOLS
In 2007-2011, routine pelvic lymphadenectomy was recommended for all patients. Selective 
para-aortic lymphadenectomy was performed in surgically eligible patients considered to be 
 Cohort 
size 
Sample type Histotype Methodology 
Study I 805 TMA All IHC 






Study III 804 TMA All IHC 
Direct sequencing 
Study IV 682 TMA Endometrioid IHC 
Direct sequencing 
MS-MLPA 
Study V 470 TMA Endometrioid IHC 
Direct sequencing 
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at elevated risk for lymphatic dissemination. Risk stratification was based on preoperative 
endometrial histology and on gross visual inspection of myometrial invasion during 
operation. From January 2012 onward, routine pelvic lymphadenectomy was abandoned 
and in patients with low-risk EC, i.e. G1-2 endometrioid carcinoma with <50% myometrial 
invasion assessed by magnetic resonance imaging, lymphadenectomy was omitted. 
Lymphadenectomy rate was 70.7% over the whole study population. Triage to adjuvant 
therapy was based on histology, stage, and type of surgery (execution or omission of 
lymphadenectomy). In patients with stage I-II endometrioid carcinoma, vaginal 
brachytherapy or whole pelvic radiotherapy was administered. Patients with stage III-IV 
endometrioid carcinoma or non-endometrioid EC of any stage received chemotherapy or a 
combination of chemotherapy and radiotherapy. 
 
FOLLOW-UP PROTOCOL AND ENDPOINTS
The standard follow-up protocol consisted of medical check-ups scheduled every 3-4 months 
for the first year and thereafter every 6-12 months for a minimum of 3 years. The physical 
examination was complemented with imaging studies when alarming symptoms/findings 
emerged. A biopsy confirmed the endometrial origin of relapse in patients with additional 
non-uterine primary tumors. Follow-up data were collected from institutional medical 
records or from primary physicians at the referring institutions. Missing data were collected 
from death certificates obtained from Statistics Finland.  
The main outcome of interest was disease-specific survival, defined as the time from surgery 
to death from EC. In Study I, cancer relapses were classified as follows: isolated vaginal 
relapse, retroperitoneal relapse (i.e. metastasis in pelvic and/or para-aortic lymph nodes, 
including those with a concomitant vaginal relapse or a lymph node metastasis extending to 
the groin), intraperitoneal relapse (including those with a metastasis in the vagina or in 
regional lymph nodes), and extra-abdominal relapses (metastases in the lung, liver, skin, 
brain etc., including those with concomitant metastasis in any other site).  
 
TMA AND IMMUNOHISTOCHEMISTRY
Histological slides were reviewed by a pathologist, and representative areas of vital 
carcinoma tissue were marked on the slides. Four 0.8-mm cores were drawn from the 
corresponding area of the paraffin blocks and were inserted in the recipient TMA block with 
a manual tissue microarrayer (Beecher MTA-1, Beecher Instruments Inc., Sun Prairie, WI, 
USA). Details on the antibodies, dilutions and scoring are shown in Table 4.  
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 Clone/Cat.no. Dilution Source Cut-off (localization) 
L1CAM 14.10 1:40 Covance ≥ 10% (membranous) 
MLH1 ES05 1:50 Dako Complete or clonal loss 
(nuclear) 
PMS2 EPR3947 1:25 Epitomics Complete or clonal loss 
(nuclear) 
MSH2 G219-1129 1:400 BD Biosciences Complete or clonal loss 
(nuclear) 
MSH6 EPR3945 1:200 Abcam Complete or clonal loss 
(nuclear) 
p53 DO-7 1:500 Dako Null or strong and diffuse 
(nuclear) 
ARID1a HPA005456 1:200 Sigma-Aldrich Complete or clonal loss 
(nuclear) 
ERa SP1 R-T-U Roche/Ventana < 10% (nuclear) 
PR 16 1:50 Novocastra < 10% (nuclear) 
PD-L1 
(chromogenic) 
SP263 R-T-U Ventana ≥ 1% (membranous) 
PD-L1 
(multiplex) 
E1L3N 1:200 CST ≥ 1% (membranous) 
CD3 MA1-82041    1:750       ThermoFisher membranous 





















Beta-catenin CAT-5H10 1:400 Zymed Any nuclear staining 
E-cadherin HECD-1 1:200 Invitrogen Complete or clonal loss 
(membranous) 
p-16 E6H4 R-T-U CINtec Histology Block type strong and 
diffuse hyperexpression 
(nuclear and cytoplasmic) 
c-erbB2 4B5 R-T-U Roche/Ventana 2+/3+ hyperexpression 
(membranous) 
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Chromogenic immunohistochemical stainings were performed at the Huslab Pathology 
Laboratory, Helsinki, Finland, with a few exceptions. L1CAM (preoperative samples) and 
ARID1a were stained at the Research Laboratories of the Departments of Obstetrics and 
Gynecology and Medical Genetics, Biomedicum, Helsinki, and L1CAM (TMA slides) at the 
Institute of Biomedical Technology, University of Tampere, Finland. Chromogenic PD-L1 
stainings were performed at Fimlab Laboratoriot Oy, Tampere, Finland. 
Immunohistochemcal scoring was carried out either by traditional microscopy or digitalized 
microscopy using WebMicroscope Software (Fimmic Oy). 
Multiplex fluorescent immunohistochemistry was performed at the Institute for Molecular 
Medicine Finland (FIMM), Helsinki. Five-channel fluorescent images were acquired using 
Metafer 5 scanning and imaging platform (MetaSystems, Alltlussheim, Germany). Image 
analysis was carried out by a pathologist. PD-L1 expression was scored separately for 
carcinoma cells, intratumoral immune cells (macrophages and T-lymphocytes), and 
combined positive scoring (CPS, i.e. the percentage of all PD-L1-positive cells relative to 
carcinoma cells).  
For stainings where an internal control was applicable (MMR protein, p53, ARID1a, ER and 
PR), samples with a completely negative internal control were discarded. All slides were 
scored blinded to the clinical data. The concordance between the staining results on TMA 
and whole sections was tested with L1CAM, which is known to present a heterogeneous 
staining pattern. Representative microphotographs of the principal immunostainings are 
depicted in the original publications I, III and IV.  
 
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
We performed ELISA to measure the level of soluble L1 in serum samples from 17 patients 
with an immunohistochemically verified L1CAM-positive and 23 patients with an L1CAM-
negative EC. Blood fractionation was carried out by centrifugation for 10 minutes at 2000g. 
We used a commercial ELISA kit (LS-F24209; LifeSpan Biosciences Inc., Seattle, WA, USA). 
Sandwich ELISA was performed on standards, controls, and samples according to the 
manufacturer’s instructions. We ran test reactions on serial dilutions and the optimal serum 
dilution was 1:2000. Duplicate wells were run for each sample. The absorbance at 450 nm 
was measured by an automatic ELISA reader (Multiskan EX; Thermo Fisher Scientific). Results 
were expressed in nanogram per milliliter according to the established standard curve. The 
limit of detection was 93.75 to 6000 pg/mL. 
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POLE AND KRAS MUTATIONAL ANALYSIS BY DIRECT SEQUENCING
For DNA extraction, a pathologist identified representative areas of formalin-fixed paraffin-
embedded tumor tissue, which were then macrodissected. DNA was extracted by the 
proteinase K/phenol-chloroform method. Direct sequencing was performed to identify POLE 
exonuclease domain hot spot mutations in exon 9 (c.857C>G, p.P286R; c.890C>T, p.S297F), 
exon 13 (c.1231G>C, p.V411L) and exon 14 (c.1366G>C, p.A456P) and KRAS hot spot 
mutations in exon 2 (c.34G>T, p.G12C; c35G>A, p.G12D; c.37G>T, p.G13T; c.38G>A, p.G13D). 
PCR products were sequenced on an ABI3730xl Automatic DNA Sequencer at the Institute 
for Molecular Medicine Finland (FIMM). Sequence graphs were analyzed both manually and 
with Mutation Surveyor (Softgenetics, State College, PA, USA).  
 
METHYLATION-SPECIFIC MULTIPLEX LIGATION-DEPENDENT 
PROBE AMPLIFICATION (MS-MLPA)
MLH1 promoter methylation status in Deng promoter regions C and D was determined by 
MS-MLPA using the SALSA MMR MS-MLPA Kit ME011 (MRC-Holland) on 250ng of DNA from 
each sample. All MS-MLPA reactions, analyses, and calculations of methylation dosage ratios 
were done according to the manufacturer's instructions. Reaction products were separated 
by capillary electrophoresis on an ABI 3730 Automatic DNA sequencer (Applied Biosystems) 
and analyzed using GeneMapper 5.0 genotyping software (Applied Biosystems). We 
considered a promoter to show methylation if the methylation dosage ratio was >0.15, 
corresponding to 15% of methylated DNA, in either region C or region D or both.  
 
STATISTICAL ANALYSIS
Data were analyzed using SPSS version 25 software (IBM Corp., Armonk, NY, USA). Statistical 
significance was set at P < 0.05 in all studies. 
In Study I, logistic regression analysis was performed to compute odds ratios along with 95% 
confidence intervals (CIs) for the associations between L1CAM expression and various 
clinicopathological risk factors and relapse patterns. We applied the Kaplan-Meier method 
and log rank test to compare differences in disease-specific survival between patients with 
L1CAM-positive and -negative ECs. The association of L1CAM expression and disease-specific 
survival within ESMO-ESGO-ESTRO risk groups was assessed by univariate Cox regression 
analysis. Multivariable Cox proportional hazard model was applied to estimate the effects 
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of various risk factors on disease-specific survival. Multiple imputation was used to account 
for missing data. 
 In Study II, Cohen κ statistic was used to measure the concordance between L1CAM 
stainings in preoperative and hysterectomy samples of individual patients. Logistic 
regression was used to test for associations between L1CAM expression in preoperative 
samples and various categorical risk parameters. Differences regarding serum levels of sL1 
(continuous variable) in patients with L1CAM-positive and negative tumors were analyzed 
using the Mann-Whitney U test. Logistic regression analysis estimated the effect (odds 
ratios) of selected parameters (L1CAM expression, tumor dimension, preoperative 
histotype, and myometrial invasion) on the risk of having advanced (stage IIIc/IV) disease. 
These odds ratios were rounded and summed to form risk scores according to alternative 
risk models. The discriminating abilities of the models were evaluated in two-tailed receiver 
operating characteristic curve analyses.  
In Study III, Pearson χ² test and Fisher exact test (two-sided) were used for comparisons of 
PD-L1 expression and various categorical variables (e.g. histological and molecular 
subgroups, disease stage). Kaplan-Meier method and log rank test were applied to compare 
differences in disease-specific survival according to histological subtype, molecular 
subgroups, quantity of intratumoral T-cell infiltrates, and PD-L1 positivity. Cohen κ statistic 
was used to measure the concordance rate between PD-L1 scorings obtained by 
conventional chromogenic immunohistochemistry and multiplex fluorescent 
immunohistochemistry.  
In Study IV, Pearson χ² test and Fisher exact test (two-sided) were used to investigate 
associations between MMR phenotype and various categorical variables (e.g. 
clinicopathological risk factors, immunological and various other biomarkers). The 
contribution of each risk factor to disease-specific survival was determined by simple and 
multivariable analyses by the Cox proportional hazard model. Kaplan-Meier method and log 
rank test were applied to compare differences in DSS according to MMR phenotype. 
In Study V, Pearson χ² test and Fisher exact test (two-sided) were used to investigate 
associations between molecular subgroups (NSMP, MMRd) and categorical variables (e.g. 
clinicopathological risk factors and various biomarkers). Kaplan-Meier method and log rank 
test were applied to compare differences in disease-specific survival according to molecular 
group and single risk factors. Multivariable analyses by the Cox proportional hazard model 
were used to investigate the independent effect of individual factors within each molecular 
group. In order to test statistical significance of differential impacts across the molecular 
groups, interaction terms including molecular group and individual risk factors were 
introduced in a multivariable model adjusting for pertinent clinicopathological factors and 
the main effects of the interaction term. 




 Pertinent clinicopathological characteristics of the study cohort are shown in Table 5.  
Table 5. Clinicopathologic data (n = 842). 
Age (years, mean ± SD) 67.5 ± 10.6 
Pelvic lymphadenectomy (number of cases, %)  469 (55.7) 
Pelvic-aortic lymphadenectomy (number of cases, %) 125 (14.8) 
Histology (number of cases, proportion) 
    Endometrioid carcinoma 
    Clear cell carcinoma 
    Serous carcinoma 
    Undifferentiated carcinoma 
    Carcinosarcoma 








Grade (number of cases, percent), endometrioid only 
     Grade 1 
     Grade 2 





Molecular classification a (number of cases, proportion) 
      POLEmut 
      MMRd 
      NSMP 






FIGO 2009 stage (number of cases, proportion) 
     IA 
     IB 
     II 
    IIIA 
    IIIB 
    IIIC1 
    IIIC2 
    IVA 











Adjuvant therapy (number of cases, proportion) 
    No adjuvant therapy 
    Vaginal brachytherapy 
    Whole pelvic radiotherapy 
    Chemotherapy 








     No 








STUDY I: L1 CELL ADHESION MOLECULE AS A PREDICTOR OF 
DISEASE-SPECIFIC SURVIVAL AND PATTERNS OF RELAPSE IN 
ENDOMETRIAL CANCER
In the whole cohort, 15% (121/805) of the tumors were L1CAM-positive (defined as ≥10% of 
the carcinoma cells). We found a statistically significant association between L1CAM 
expression and the presence of several poor prognostic variables (advanced stage, nodal 
dissemination, high-grade endometrioid/non-endometrioid histology, LVSI, cervical stromal 
invasion, positive peritoneal cytology, and age >65 years). L1CAM expression predicted poor 
disease-specific survival in endometrioid EC but not in non-endometrioid EC (Figure 4). 
Multivariable survival analysis confirmed the role of L1CAM as an independent poor 
prognostic factor after controlling for all principal clinicopathologic risk factors. During the 
median follow-up time of 51 (range 1-98) months, a relapse was diagnosed in 11.2% 
(68/606) of the patients with stage I cancer. Distant (extra-abdominal) metastases were 
more frequent in L1CAM-positive than L1CAM-negative stage I endometrioid carcinomas 
(P<0.0001). The frequency of other types of metastasis (vaginal, retroperitoneal and 













Figure 4. Kaplan-Meier curves for disease-specific survival according to L1CAM 
expression in A) endometrioid EC (n=735) and B) non-endometrioid EC (n=70). 
  P<0.001 P=0.934 A B 
                      RESULTS 
33 
 
STUDY II: PREOPERATIVE RISK STRATIFICATION OF 
ENDOMETRIAL CARCINOMA: L1CAM AS A BIOMARKER
Of the 241 preoperative EC samples, 64 (26.6%) were L1CAM-positive. L1CAM positivity was 
more frequent in G3 endometrioid (27.6%) and non-endometrioid (68.4%) carcinomas than 
in G1-2 endometrioid carcinoma (22.3%, P < 0.0001). L1CAM expression in paired pre- and 
postoperative carcinoma samples showed moderate concordance (as defined by Landis and 
Koch, kappa=0.586, P < 0.0001) [125]. 
Preoperative L1CAM positivity correlated with the presence of negative prognostic factors 
(non-endometrioid histology, lymph node involvement, older age, advanced stage and 
positive peritoneal cytology).  Integrating L1CAM into risk assessment models based on 
histotype, myometrial invasion and/or tumor diameter did not significantly improve the 
ability of the models to predict advanced stage (Table 6). Tumoral expression of L1CAM and 
serum levels of L1 did not show significant correlation (P = 0.786). 
Table 6. Areas under curve (AUC) for risk models predicting stage IIIC–IV endometrial 
carcinoma. HRH=high risk histology (endometrioid G3/non-endometrioid), MI=myometrial invasion, 
L1CAM=L1 cell adhesion molecule, TD=tumor diameter.  
STUDY III: PD-L1 EXPRESSION IN ENDOMETRIAL CARCINOMA 
CELLS AND INTRATUMORAL IMMUNE CELLS: DIFFERENCES 
ACROSS HISTOLOGIC AND TCGA-BASED MOLECULAR SUBGROUPS
In our unselected cohort of ECs, PD-L1 positivity (≥1% of the cells) was more frequent in 
immune cells (27.7% of the cases) than in carcinoma cells (8.6%). CPS ≥ 1% was detected in 
19.4% of the samples.  
Risk assessment model AUC (95% CI) P (two-tailed) 
1. HRH-TD5cm-MI33%-L1CAM 0.879 (0.828-0.930)  
2. HRH-TD5cm-MI33% 0.870 (0.813-0.928) 0.882 vs. model 1 
3. HRH-TD5cm-L1CAM 0.852 (0.778-0.925)  
4. HRH-TD5cm 0.818 (0.730-0.906) 0.613 vs. model 3 
5. HRH-TD2cm-MI50%-L1CAM 0.841 (0.777-0.905)  
6. HRH-TD2cm-MI50% 0.805 (0.717-0.894) 0.602 vs. model 5 
7. HRH-MI50%-L1CAM 0.833 (0.770-0.896)  




Molecular, histological, and disease stage-based subgroups of EC showed significant 
differences in PD-L1 expression profiles. Among the TCGA subgroups, POLEmut and MMRd 
tumors exhibited higher rates of PD-L1 expression determined by immune cell score and CPS 
(Figure 5) and were more likely to display the PD-L1 inflamed phenotype (PD-L1 expression 
associated with dense T-cell infiltrates, P<0.001). No differences were found between the 
subgroups regarding PD-L1 expression in carcinoma cells. Within histological subgroups, 
non-endometrioid carcinomas presented more frequent PD-L1 positivity in immune cells 
and CPS. Relative to early-stage disease, advanced carcinomas were more likely to display 












PD-L1 expression did not correlate with outcome. In the concordance analysis between 
multiplex IHC and conventional chromogenic IHC, CPS outperformed the scoring system 
based on carcinoma cell positivity, which requires discerning positive carcinoma cells and 
immune cells (κ=0.540 for CPS and κ=0.279 for carcinoma cell scoring). This result indicates 
that when using conventional chromogenic IHC for PD-L1 scorings, CPS provides more 
accurate scorings.  
 
Figure 5. Frequency of PD-L1 positivity in carcinoma cells (p=0.366), ICs (p<0.001), CPS (p<0.001) 
and presence of heavy T cell infiltrates (p=0.014) according to molecular subgroups. POLEmut = 
mutated POLE, MMRd= MMM deficient, NSMP = no specific molecular type, p53ab = p53 
aberrant. Ca=carcinoma cells, ICs=immune cells, CPS=combined positive score, TILs=tumor 
infiltrating lymphocytes. With permission from Am J Surg Pathol. 
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STUDY IV: CLINICOPATHOLOGICAL SIGNIFICANCE OF DEFICIENT 
DNA MISMATCH REPAIR AND MLH1 PROMOTER METHYLATION IN 
ENDOMETRIOID ENDOMETRIAL CARCINOMA
In our cohort of 682 unselected endometrioid ECs, 244 (35.8%) of the cases presented loss 
of MMR protein expression determined by IHC. The frequencies of specific patterns of 
protein loss were as follows: MLH1+PMS2 in 29.8%, PMS2 in 0.9%, MSH2+MSH6 in 1.3%, 
MSH6 in 2.8%, and multiple abnormalities in 0.9% of cases. Of the 244 MMRd ECs, 
approximately 75% were associated with MLH1 promoter methylation.  
We found an association between MMR deficiency and older age, high grade of 
differentiation (G3), advanced stage (II-IV), larger tumor size, abundant tumor infiltrating 
lymphocytes, PD-L1 positivity in immune cell score and CPS, p53wt, negative L1CAM, and 
ARID1a loss. MMRd-Met phenotype correlated with older age and larger tumor size and 
predicted poor disease-specific survival in the whole cohort (Figure 6). In the MMRd 
subgroup, significant survival differences were not found between patients with methylated 
tumors and those with non-methylated tumors. Univariate analysis restricted to MMRd 
cases showed significant correlations between poor disease-specific survival and disease 
stage II-IV, high grade (G3), deep myometrial invasion, LVSI, tumor size ≥ 2cm, positive 







Figure 6. Kaplan-Meier curves for 
disease-specific survival according 





STUDY V: DIFFERENTIAL IMPACT OF CLINICOPATHOLOGICAL 
RISK FACTORS WITHIN THE TWO LARGEST TCGA-RELATED 
MOLECULAR SUBGROUPS OF ENDOMETRIAL CARCINOMA 
Patients with MMRd EC were more likely to be >65 years of age and their tumors were more 
frequently high grade, PR-negative and E-cadherin-negative than patients with NSMP EC. 
NSMP cases more frequently showed nuclear beta-catenin positivity. 
In Kaplan-Meier analysis, disease-specific survival curves according to TCGA-based 
molecular subgroups segregated expectedly; POLEmut cases had an excellent outcome, 
followed by NSMP and MMRd, with p53abn presenting the worst prognosis (P=0.001). In 
multivariable analysis adjusted for stage, grade, myometrial invasion, LVSI, and adjuvant 
treatment, the effect of the molecular class (NSMP vs MMRd) became non-significant 
(P=0.101).  
In subgroup-specific Cox regression analysis adjusted for confounders, high grade (G3) and 
p16 hyperexpression remained significant predictors of poor disease-specific survival in 
NSMP. In the MMRd group, advanced disease stage, deep myometrial invasion, LVSI, and 
loss of E-cadherin were independent predictors. In the interaction analysis, the effect of G3 
and p16 was significantly modified by the molecular subgroup with a stronger effect in the 
NSMP group (P=0.016 and P=0.033 for the interaction term, respectively) than in the MMRd 
group. Univariate disease-free survival curves according to molecular subgroup, grade of 










Figure 7. Kaplan-Meier curves for disease-specific survival according to TCGA-based molecular 
subgroups, grade of differentiation (left), and p16 expression (right). Yellow=NSMP; green=MMRd, 
wt=wild type. 





The goal of personalized medicine is to offer optimal treatment to each patient. Targeted 
management of EC requires accurate risk stratification methods, which will reduce under 
and overtreatment in both operative and postoperative settings. Knowledge of the 
molecular events potentially involved in the pathogenesis of individual carcinomas may also 
facilitate the selection of a specific treatment modality. This study explores the prognostic 
value of L1CAM as both a pre- and postoperative marker. Further, we investigated the 
prognostic impact of single risk factors across the two largest TCGA-based subgroups (NSMP 
and MMRd) and the significance of MLH1 methylation status in MMRd EC. Lastly, we profiled 
the expression of PD-L1, an immunotherapy target molecule, across histological and TCGA 
subclasses.  
 
L1CAM IN PREOPERATIVE RISK ASSESSMENT OF ENDOMETRIAL 
CARCINOMA
As patients with clinically early-stage EC appear not to benefit from routine 
lymphadenectomy, biomarkers discerning patients with a high risk of nodal metastasis could 
help avoid unnecessary radical surgery with a significant complication risk [1, 2]. Currently 
the decision on lymphadenectomy is mainly based on the estimated depth of myometrial 
invasion, presence of cervical stromal invasion, and tumor histotype determined by an 
endometrial biopsy or curettage specimen.  
With regard to histotype, the concordance between preoperative samples and final 
hysterectomy samples is only moderate [5]. In our whole study cohort, 12.7% of the 
preoperative low-risk (G1-2 endometrioid carcinoma) cases were upgraded to high-risk 
histology in postsurgical assessment (unpublished data). Similarly, 19.0% of the preoperative 
high-risk histotypes were downgraded in hysterectomy samples (unpublished data). In the 
population of Study II, the concordance between preoperative and postoperative 
assessment of L1CAM positivity was slightly superior to that of high-risk histotype (κ =0.586 
and κ =0.551, respectively). By comparison, an earlier study found excellent agreement 
(κ=0.86) between pre- and postoperative samples categorized by ProMisE molecular 
classifier [126]. We observed a higher frequency of L1CAM positivity in preoperative samples 
(26.6%) than in hysterectomy samples (15% in the TMA). Our TMA-based result is 
comparable to the prevalence of L1CAM positive tumors (17%) observed in a large non-TMA 
study including ECs of all stages and histotypes [117]. This finding suggests that biopsy-




Finally, we investigated L1CAM positivity in preoperative EC samples regarding its capability 
to predict the need for lymphadenectomy. We found an association between preoperative 
tumoral L1CAM positivity and nodal metastases, which has been confirmed in a later study 
[127]. However, incorporating L1CAM into conventional preoperative stratification models 
did not improve the capacity of the model to predict advanced disease. Further studies are 
needed to explore the value of L1CAM within molecular-based stratification methods should 
these prove to be superior to conventional preoperative algorithms.  
 
L1CAM IN POSTOPERATIVE RISK ASSESSMENT OF ENDOMETRIAL 
CARCINOMA
In the postoperative setting, further stratification of patients is needed to select appropriate 
adjuvant treatment. At present, risk assessment is based on disease stage and histotype, 
grade, and presence or absence of LVSI in early-stage disease. As histotype, grading and LVSI 
suffer from limited reproducibility, molecular markers may offer more objective tools for 
this stratification [59, 61, 128].  
Our results corroborated the findings of previous studies where L1CAM appeared to be a 
strong prognostic factor in EC [114-116]. L1CAM positivity was more frequent in non-
endometrioid (53.5%) than endometrioid (10.4%) subtype of EC. Nonetheless, our subgroup 
analysis and the study by Van der Putten et al. [117] demonstrated a prognostic effect only 
in endometrioid EC, not in non-endometrioid cases. Given the compelling data on L1CAM, it 
has been incorporated into the molecular treatment algorithm of the ongoing PORTEC-4 
trial, which also includes TCGA-based molecular classes [129]. In the trial algorithm applied 
on early-stage ECs, L1CAM is considered a high-risk feature along with LVSI and p53abn.  
L1CAM is a membrane glycoprotein that belongs to the immunoglobulin superfamily and its 
membranous form functions as a cell surface adhesion molecule [130].  In addition, cleavage 
enzymes and exosomes can release the ectodomain of L1CAM from cell surface into the 
surrounding matrix, where it appears to promote cell migration [130] Soluble L1 has been 
detected in serum samples from cancer patients, but not in samples from healthy subjects, 
suggesting a potential role of L1 as a diagnostic or follow-up marker [131]. In our cohort, the 
concentrations of soluble L1 in the serum samples did not correlate with tumoral L1CAM 
status.  
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DIFFERENTIAL IMPACT OF RISK FACTORS WITHIN TCGA-BASED 
MOLECULAR SUBCLASSES OF ENDOMETRIAL CARCINOMA 
In 2013, TCGA established four new pathogenetically and prognostically distinct molecular 
subclasses of EC. Later studies have demonstrated significant differences between the 
groups regarding response to adjuvant radiotherapy, chemotherapy, expression of 
immunotherapy target molecules, and homologous recombination deficiency [77, 78, 94, 
95, 98, 105, 132, 133]. These findings suggest that molecular subgroups should be taken into 
account when selecting adjuvant treatment.  
The present study corroborated the findings of the original TCGA study and later related 
studies, where the prognosis was excellent in the POLEmut group, intermediate in the NSMP 
and MMRd groups, and poor in the aggressive p53abn subgroup of EC [8, 79, 80, 134]. In a 
previous meta-analysis including six TCGA classification-based studies, the relationship 
between molecular group and survival appeared to be independent of clinicopathological 
risk factors in the POLEmut group [81]. By contrast, the negative effect of MMRd (compared 
with NSMP) was related to clinicopathological risk factors, which are more frequently 
present in this subgroup [80, 81]. P53abn remained an independent predictor of survival 
after adjustment for other factors, but the effect was aggravated by the frequent presence 
of other negative prognostic factors. In this cohort, a similar result was seen, as the impact 
of the molecular group (MMRd vs NSMP) became insignificant after adjustment for the main 
clinicopathological risk factors.  
Optimal treatment algorithms will presumably integrate molecular classifiers with selected 
clinicopathological factors. The value of single risk factors, including ancillary molecular 
markers, will need to be re-examined within the context of molecular subgroups. Along with 
TCGA subclasses and L1CAM, the ongoing PORTEC-4 trial has incorporated CTNNB1 (β-
catenin) in the treatment algorithm [129]. Our results suggest that also p16 expression may 
have prognostic value in NSMP EC. In a previous study on ovarian carcinomas, strong and 
diffuse (block type) p16 hyperexpression appeared to predict poor survival in endometrioid 
and clear cell carcinoma and both hyperexpression and complete absence of p16 expression 
(as opposed to heterogeneous staining) were associated with poor survival in low-grade 
serous carcinoma [135]. Prognostic significance of these various staining patterns is 
unknown in EC. As p16 negativity was extremely rare (1.7%) in our samples and it did not 
improve the ability to discern outcomes, we only considered strong and diffuse p16 
hyperexpression as an abnormal staining result. 
 Given the heterogeneity of the molecular EC subclasses, ideal risk assessment algorithms 
may differ between the molecular subgroups. Therefore, molecular group-specific research 
efforts are needed to clarify the relevance of individual risk factors within each subgroup. To 




factors and ancillary biomarkers within NSMP and MMRd subclasses of EC. The observed 
interaction effect between molecular class and single risk factors demonstrates the 
importance of treating molecular subclasses of EC as separate disease entities, within which 
the relative weights of various risk factors need to be determined. Multi-cohort studies with 
higher statistical power may help reveal ulterior interaction effects between molecular 
groups and other factors.  
 
SIGNIFICANCE OF MLH1 METHYLATION STATUS IN MMRD
ENDOMETRIAL CARCINOMA
MMRd carcinomas may arise from two distinct pathogenetic pathways, i.e. methylation or 
mutation of MMR genes. Lynch syndrome-associated EC is typically driven by mutation. The 
majority of sporadic cases are associated with MLH1 promoter methylation, although 
biallelic somatic mutations occur. Future studies will establish whether the MLH1 
methylated phenotype of EC is a manifestation of a general hypermethylation tendency 
(CpG island methylator phenotype), as described for colorectal carcinoma [136]. In MMRd 
colorectal carcinoma, differences between Lynch syndrome and sporadic cases have been 
reported as regards histology, molecular features, and (possibly age-dependent) prognostic 
effect [137-140]. Little is known about the clinicopathological significance of the 
pathogenetic processes underlying the MMRd phenotype in EC.  
In this study cohort, methylated MMRd phenotype correlated with older age and larger 
tumor size. Methylation-linked MMRd independently predicted poor disease-specific 
survival compared with MMR intact EC, but we did not find significant survival differences 
between methylated and non-methylated MMRd EC.  In previous studies, MLH1 methylated 
EC appeared to present weaker tumoral T-cell inflammation than mutation-linked 
(hereditary) MMRd EC [108, 141]. In our study, a higher quantity of tumor infiltrating T-
lymphocytes and PD-L1 expression correlated with MMR deficiency in general, but not with 
MLH1 methylation status. Further studies are needed to explore eventual correlations 
between MMR and MLH1 methylation status and sensitivity to adjuvant therapies.  
 
IMMUNOTHERAPY IN ENDOMETRIAL CARCINOMA: PD-L1
Promising results have been obtained from phase I-II clinical trials investigating the use of 
anti PD-1/PD-L1 agents in advanced EC. Overall response rates of 13-57% have been 
reported with mild adverse effects (e.g. fatigue, pruritus, pyrexia, and anorexia) [75, 142, 
143]. Several ongoing phase I-II trials for advanced or recurrent EC investigate different anti 
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PD-1 agents in monotherapy (NCT02628067, NCT02899793, NCT02728830, NCT03241745, 
NCT03474640, NCT02715284). Future studies will also clarify whether the therapeutic effect 
can be enhanced by combining various modalities of immunotherapy, chemotherapy and 
radiotherapy. In fact, an ongoing trial is investigating the combination of anti PD-1 with 
traditional chemotherapy (NCT02549209) and anti PD-L1 agent with an anti CTLA-4 antibody 
(NCT03015129). Two recruiting phase III trials are exploring the combination of anti-PD-L1 
therapy with the conventional chemotherapy treatment (NCT03914612, NCT03981796). 
Cancer trials have demonstrated a correlation between PD-L1 expression levels and the 
efficacy of anti-PD-1/PD-L1 immunotherapy in various cancer types [88, 144, 145]. In trials 
conducted mainly on non-endometrial cancer types, response rates to pembrolizumab (anti-
PD1 agent) appear to correlate with PD-L1 expression levels in carcinoma cells, whereas the 
response to atezolizumab (anti-PD-L1 agent) appears to correlate with PD-L1 positivity on 
immune cells rather than carcinoma cells [88, 145]. The reported prevalence of PD-L1 
positivity in EC varies considerably between studies (0.9% to 48% regarding expression in 
carcinoma cells). Along with different cut-offs for IHC, different antibody clones explain 
some of the variation since considerable interassay variation has been reported [146, 147]. 
Further, conventional chromogenic IHC for PD-L1 suffers from limited reproducibility 
especially with cut-offs for positivity as low as 1% [92]. This problem is related to the 
difficulty of discerning PD-L1 positive carcinoma cells from PD-L1-positive immune cells 
(mainly macrophages). To overcome this limitation, we adopted multiplex IHC, which 
provides cell type-specific staining of PD-L1, leading to more accurate scores. As observed in 
our study and others [95, 96, 99], intratumoral immune cells display more frequent (27.7%) 
PD-L1 positivity than carcinoma cells (8.6%). In particular, strong positivity in carcinoma cells 
was rare (0.5%). Further, we performed concordance analysis between conventional and 
multiplex IHC using various scoring methods, i.e. separate scoring of carcinoma cell and 
immune cell positivity and combined positivity. Combined scoring showed better 
concordance, suggesting it may improve reproducibility of conventional IHC scorings, as 
multiplex IHC is often not available in routine diagnostics. As optimal scoring methods and 
cut-offs may be tumor type-specific, future studies should consider various scoring methods 
when estimating the response rates of EC patients receiving immunotherapy.  
Clinical trials have reported particularly promising (>50%) overall response rates to immune 
check-point inhibition in patients with MMRd tumors, including MMRd EC [74–76, 142]. 
MMRd tumors are considered highly immunogenic due to their elevated mutational 
frequency and the abundance of predicted neoantigens and T-cell infiltration. An analogous 
immunological microenvironment has been observed in POLEmut EC [94]. Our study 
corroborated these findings, as we observed a T-cell-inflamed PD-L1-positive phenotype 
more frequently in the above molecular subgroups. As MLH1 methylation status of MMRd 
tumors did not correlate with immunological features, methylation analysis may not provide 




POLEmut EC may not require adjuvant therapy. The need for alternative treatment options 
is more obvious in the aggressive non-endometrioid ECs, where PD-L1 positivity was more 
frequent (in immune cells and CPS) than in endometrioid EC.  
STUDY STRENGTHS AND LIMITATIONS
Our large and unselected study cohort includes patients with ECs of all histotypes and 
disease stages. Histological diagnosis was reviewed by an experienced gynecopathologist. 
Patients were treated in a single center with well-defined diagnostic and operative 
standards. The relatively high lymphadenectomy rate (70.7%) reduced the risk of 
understaging due to occult nodal disease. Follow-up data were adequately updated and 
follow-up times were long. As in any retrospective study, selection bias may have been 
produced by data collection from a single tertiary referral center. However, the principal 
clinicopathological characteristics of the cohort were comparable to other large unselected 
cohorts, excluding substantial sampling bias [148, 149]. Comprehensive clinicopathological 
data enabled multivariable regression models to control for confounding at the analysis 
stage. Exhaustively documented causes of death allowed us to measure disease-specific 
survival instead of the less specific overall survival. In an EC study this is particularly 
important since the prognosis of the disease is relatively good, but the patients are often 
elderly and have critical comorbidities. In fact, in EC studies investigating overall survival 
rather than disease-specific survival, approximately half of the deaths are attributed to 
causes other than EC [150].  
TMA-based methodology allowed us to perform numerous immunohistochemical stainings 
on a large number of samples. Our TMA included tumor samples from 87.3% of the patients 
forming the unselected study cohort. Remaining cases were mainly discarded due to tumor 
size too small to biopsy. Thus, the proportion of early stage (stage Ia) disease resulted slightly 
underestimated. The challenge with the TMA method lies in the difficulty of assessing 
heterogeneous stainings. However, it has been shown that TMAs based on three core 
biopsies provide representative results in over 95% of the cases even for heterogeneous 
stainings [151-153]. To increase sensitivity, specificity, and reproducibility, we included four 
separate cores from each tumor in our TMA. κ statistics confirmed a high concordance 
between our TMA and corresponding whole-section staining results with regard to a 
notoriously heterogeneous antigen, L1CAM.  
 




Given the limitations of current risk stratification methods and the compelling results 
reported by various research groups for TCGA classification-based molecular methods, 
molecular biomarkers will presumably be incorporated into the risk stratification algorithms 
of EC. The combination of conventional risk factors and ancillary molecular markers forming 
the optimal treatment algorithm may differ between TCGA molecular classes. Thus, future 
studies will need to consider potential modifying effects that molecular subgroups exert on 
the impact of single risk factors. In order to achieve high statistical power, molecular 
subgroup-specific analyses necessitate large sample sizes, which could be provided by multi-
cohort studies.  
Whether performing molecular classification preoperatively offers advantages over 
postoperative testing, remains to be established. Further, the relationship between TCGA 
molecular classes and sensitivity to chemotherapy, radiotherapy and immunotherapy needs 
to be assessed in prospective trials. Similarly, further studies investigating the role of 
methylation status in predicting treatment responses in MMRd EC are warranted. Whether 
the excellent prognosis of POLEmut EC is attributed to the indolent nature of the disease or 
to higher sensitivity to adjuvant treatment must be clarified in order to omit potentially 
unnecessary therapies. Without a doubt, molecular profiling of EC has introduced a new era 







This study explored molecular biomarkers that could be used for prognostication and 
personalized treatment planning of EC. The results can be summarized as follows: 
I Tumoral L1CAM expression is associated with the presence of aggressive 
features and occurrence of distant relapses in EC. L1CAM expression 
independently predicts poor survival in endometrioid EC, but not in non-
endometrioid EC.  
II L1CAM positivity detected in a preoperative EC sample is associated with the 
presence of negative prognostic factors including lymph node metastases. 
However, integrating L1CAM into conventional risk models does not improve 
the ability to stratify patients to lymphadenectomy.  
III POLEmut and MMRd present more frequent PD-L1 positivity and abundant T-
cell infiltrates compared with other TCGA subgroups of EC. Differential PD-L1 
expression in molecular subclasses of EC suggests that in future studies the 
response to immunotherapy should be examined in a subclass-specific 
manner. A combined positive scoring method of chromogenic PD-L1 stainings 
may be more accurate than cell type-specific scoring methods.  
IV In endometrioid EC, the MMRd phenotype correlates with the presence of 
conventional risk factors (older age, high grade, advanced stage, larger tumor 
diameter). MLH1 methylation predicts poor disease-specific survival compared 
with MMR intact EC; however, within MMRd ECs, methylation status does not 
have a significant effect on disease-specific survival. Methylation status does 
not correlate with immunological features.  
V Molecular subgroups modify the prognostic effect of single risk factors. 
Subgroup-specific studies are needed to determine the relative impact of each 
factor in order to formulate an optimal treatment algorithm for each molecular 
class of EC. 
 





This study was carried out in 2013-2021 at the Department of Pathology in Helsinki 
University Hospital.  
 
I wish to express my gratitude to the Head of Pathology, Docent Kaisa Salmenkivi and the 
acting Head of Pathology, Docent Päivi Heikkilä for their positive attitude towards research 
and for providing research facilities during my specialist training and as a specialist.  
My warmest appreciation goes to my supervisors Docent Ralf Bützow and Docent Mikko 
Loukovaara. I am deeply grateful to Docent Ralf Bützow for always having time for 
illuminating and reassuring conversations. I admire his logic and excellent skills in clinical 
pathology. I also appreciate his ability to encourage independent work while providing 
valuable guidance towards better scientific thinking and writing.  I warmly thank Docent 
Mikko Loukovaara for dedicating time and effort to answering my innumerable questions. 
His vast clinical knowledge has helped me improve my work and I am particularly grateful 
for him opening the fascinating world of statistics to me.  
My heartfelt thanks go to the co-authors of these studies. I wish to express my appreciation 
to Taru Tuomi for her important contribution to this cohort and for warm conversations. My 
sincere thanks go to Pia Vahteristo and Terhi Ahvenainen for sharing their expertise in 
genetic data analysis and to Päivi Peltomäki for her expertise in methylation analyses. I thank 
Teijo Pellinen for providing valuable multiplex immunohistochemistry and Synnöve Staff and 
Jorma Isola for providing high quality immunohistochemical slides.  
I cordially thank the official reviewers of this thesis, Professor Ilmo Leivo and Docent Maarit 
Anttila for their dedicated and professional evaluation that helped me improve this work. I 
also express my gratitude to Docent Annika Auranen for agreeing to act as the faculty 
opponent at the public defense. 
Skillful and dedicated laboratory technicians Gynel Arifdshan and Annikki Löfhjelm are kindly 
acknowledged for all laboratory work and assistance. I thank Satu Remes and Mia Kero for 
their support with immunohistochemistry. Minna Hänninen, Sinikka Kyyrönen and Antti 
Ketola deserve warm thanks for their assistance in the first steps of the TMA construction. 






I am thankful to all my colleagues in the Huslab laboratories of Pathology. You created the 
warm atmosphere that surrounded me before, during and after this project.  Ari Ristimäki, 
Sonja Boyd, Jouko Lohi and Jaana Hagström deserve a special thank for advice and 
encouraging conversations. 
I am deeply grateful for all my loved ones and my dear friends who bring affection, happiness 
and fun into my life. Kati, you have relentlessly supported me in this long project, but 
foremost you are a true friend. Riitta and Sanna always fill up my cup of optimism when I 
most need it. Sara dedicated her time to answer my numerous questions on statistics. I thank 
Nyyti and Kaapo the dogs for taking me out even on rainy days and for teaching me about 
the power of living in the moment. I am eternally thankful to my late mother who always 
believed in me.  
This study was financially supported by the Medical Research Fund of Helsinki University 
Hospital and the Finnish Cancer Foundation. Their support is kindly acknowledged. 
 














            [1]  ASTEC study group, Kitchener, H., Swart, A.M., Qian, Q., Amos, C., Parmar, M.K., Efficacy of 
systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a 
randomised study, Lancet. 373 (2009) 125-136 
            [2]  Benedetti Panici, P., Basile, S., Maneschi, F., Alberto Lissoni, A., Signorelli, M., Scambia, G., 
Angioli, R., Tateo, S., Mangili, G., Katsaros, D., Garozzo, G., Campagnutta, E., Donadello, N., 
Greggi, S., Melpignano, M., Raspagliesi, F., Ragni, N., Cormio, G., Grassi, R., Franchi, M., 
Giannarelli, D., Fossati, R., Torri, V., Amoroso, M., Croce, C., Mangioni, C., Systematic pelvic 
lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: 
randomized clinical trial, J.Natl.Cancer Inst. 100 (2008) 1707-1716 
            [3]  Burke, W.M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A.B., Brewer, M., Boruta, 
D., Villella, J., Herzog, T., Abu Shahin, F., Endometrial cancer: A review and current 
management strategies: Part I, Gynecol.Oncol. 134 (2014) 385-392 
            [4]  Burke, W.M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A.B., Brewer, M., Boruta, 
D., Herzog, T.J., Shahin, F.A., Endometrial cancer: A review and current management 
strategies: Part II, Gynecol.Oncol. 134 (2014) 393-402 
            [5]  Visser, N.C.M., Reijnen, C., Massuger, L.F.A.G., Nagtegaal, I.D., Bulten, J., Pijnenborg, 
J.M.A., Accuracy of Endometrial Sampling in Endometrial Carcinoma: A Systematic Review 
and Meta-analysis , Obstet.Gynecol. 130 (2017) 803-813 
            [6]  Mariani, A., Dowdy, S.C., Cliby, W.A., Gostout, B.S., Jones, M.B., Wilson, T.O., Podratz, K.C., 
Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift 
in surgical staging, Gynecol.Oncol. 109 (2008) 11-18 
            [7]  Bendifallah, S., Ouldamer, L., Lavoue, V., Canlorbe, G., Raimond, E., Coutant, C., Graesslin, 
O., Touboul, C., Collinet, P., Daraï, E., Ballester, M., Patterns of recurrence and outcomes in 
surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO 
Consensus Conference risk groups: Results from the FRANCOGYN study Group, 
Gynecologic Oncology. 144 (2017) 107-112.  
            [8]  Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, 
R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., Yau, C., Laird, P.W., 
Ding, L., Zhang, W., Mills, G.B., Kucherlapati, R., Mardis, E.R., Levine, D.A., Integrated 
genomic characterization of endometrial carcinoma , Nature. 497 (2013) 67-73 
            [9]  Siegel, R.L., Miller, K.D., Jemal, A., Cancer Statistics, 2017, CA Cancer.J.Clin. 67 (2017) 7-30 






          [11]  DiSaia, P.J., Creasman, W.T. (Eds.), Clinical gynecologic oncology, 8th pages 141-174 ed., 
Elsevier/Saunders, Philadelphia, 2012 
          [12]  https://seer.cancer.gov/archive/csr/1975_2014/results_merged/sect_07_corpus_uteri.pdf 
          [13] Setiawan, V.W., Yang, H.P., Pike, M.C., McCann, S.E., Yu, H., Xiang, Y.B., Wolk, A., 
Wentzensen, N., Weiss, N.S., Webb, P.M., van den Brandt, P.A., van de Vijver, K., 
Thompson, P.J., Australian National Endometrial Cancer Study Group, Strom, B.L., Spurdle, 
A.B., Soslow, R.A., Shu, X.O., Schairer, C., Sacerdote, C., Rohan, T.E., Robien, K., Risch, H.A., 
Ricceri, F., Rebbeck, T.R., Rastogi, R., Prescott, J., Polidoro, S., Park, Y., Olson, S.H., Moysich, 
K.B., Miller, A.B., McCullough, M.L., Matsuno, R.K., Magliocco, A.M., Lurie, G., Lu, L., 
Lissowska, J., Liang, X., Lacey, J.V.,Jr, Kolonel, L.N., Henderson, B.E., Hankinson, S.E., 
Hakansson, N., Goodman, M.T., Gaudet, M.M., Garcia-Closas, M., Friedenreich, C.M., 
Freudenheim, J.L., Doherty, J., De Vivo, I., Courneya, K.S., Cook, L.S., Chen, C., Cerhan, J.R., 
Cai, H., Brinton, L.A., Bernstein, L., Anderson, K.E., Anton-Culver, H., Schouten, L.J., Horn-
Ross, P.L., Type I and II endometrial cancers: have they different risk factors? , J.Clin.Oncol. 
31 (2013) 2607-2618 
          [14]  Kaaks, R., Lukanova, A., Kurzer, M.S., Obesity, endogenous hormones, and endometrial 
cancer risk: a synthetic review, Cancer Epidemiol.Biomarkers Prev. 11 (2002) 1531-1543 
          [15]  Friberg, E., Orsini, N., Mantzoros, C.S., Wolk, A., Diabetes mellitus and risk of endometrial 
cancer: a meta-analysis, Diabetologia. 50 (2007) 1365-1374 
          [16]  Collaborative Group on Epidemiological Studies on Endometrial Cancer, Endometrial 
cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women 
with endometrial cancer from 36 epidemiological studies, Lancet Oncol. 16 (2015) 1061-
1070 
          [17]  Michels, K.A., Pfeiffer, R.M., Brinton, L.A., Trabert, B., Modification of the Associations 
Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and 
Colorectal Cancers, JAMA Oncol. 4 (2018) 1623-1624 
          [18]  Weiderpass, E., Adami, H.O., Baron, J.A., Magnusson, C., Lindgren, A., Persson, I., Use of 
oral contraceptives and endometrial cancer risk (Sweden), Cancer Causes Control. 10 
(1999) 277-284 
          [19]  Jareid, M., Thalabard, J.C., Aarflot, M., Bovelstad, H.M., Lund, E., Braaten, T., 
Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of 
ovarian and endometrial cancer, without increased risk of breast cancer. Results from the 
NOWAC Study, Gynecol.Oncol. 149 (2018) 127-132 
          [20]  Soini, T., Hurskainen, R., Grenman, S., Maenpaa, J., Paavonen, J., Pukkala, E., Cancer risk in 
women using the levonorgestrel-releasing intrauterine system in Finland, Obstet.Gynecol. 
124 (2014) 292-299 
                       REFERENCES 
49 
 
          [21]  Tempfer, C.B., Hilal, Z., Kern, P., Juhasz-Boess, I., Rezniczek, G.A., Menopausal Hormone 
Therapy and Risk of Endometrial Cancer: A Systematic Review, Cancers (Basel). 12 (2020) 
2195 
          [22]  Cohen, I., Endometrial pathologies associated with postmenopausal tamoxifen treatment, 
Gynecol.Oncol. 94 (2004) 256-266 
          [23]  Hu, R., Hilakivi-Clarke, L., Clarke, R., Molecular mechanisms of tamoxifen-associated 
endometrial cancer (Review), Oncol.Lett. 9 (2015) 1495-1501 
          [24]  Chlebowski, R.T., Schottinger, J.E., Shi, J., Chung, J., Haque, R., Aromatase inhibitors, 
tamoxifen, and endometrial cancer in breast cancer survivors, Cancer. 121 (2015) 2147-
2155 
          [25]  Fabian, C.J., The what, why and how of aromatase inhibitors: hormonal agents for 
treatment and prevention of breast cancer, Int.J.Clin.Pract. 61 (2007) 2051-2063 
          [26]  Teng, F., Ma, X., Yu, X., Yan, Y., Zhao, J., Gao, J., Gao, C., Wang, Y., Tian, W., Xue, F., High 
serum Androgen and Insulin concentrations increase the tendency of Endometrial 
Carcinoma, J.Cancer. 11 (2020) 5656-5664 
          [27]  Loukovaara, M., Carson, M., Adlercreutz, H., Regulation of sex hormone-binding globulin 
secretion and gene expression by cycloheximide in vitro, J.Steroid Biochem.Mol.Biol. 54 
(1995) 141-146 
          [28]  Michels, K.A., Brinton, L.A., Wentzensen, N., Pan, K., Chen, C., Anderson, G.L., Pfeiffer, 
R.M., Xu, X., Rohan, T.E., Trabert, B., Postmenopausal Androgen Metabolism and 
Endometrial Cancer Risk in the Women's Health Initiative Observational Study, JNCI 
Cancer.Spectr. 3 (2019) pkz029 
          [29]  Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., Comeras, I., La 
Jeunesse, J., Nakagawa, H., Westman, J.A., Prior, T.W., Clendenning, M., Penzone, P., 
Lombardi, J., Dunn, P., Cohn, D.E., Copeland, L., Eaton, L., Fowler, J., Lewandowski, G., 
Vaccarello, L., Bell, J., Reid, G., de la Chapelle, A., Screening for Lynch syndrome (hereditary 
nonpolyposis colorectal cancer) among endometrial cancer patients , Cancer Res. 66 (2006) 
7810-7817 
          [30]  Buchanan, D.D., Tan, Y.Y., Walsh, M.D., Clendenning, M., Metcalf, A.M., Ferguson, K., 
Arnold, S.T., Thompson, B.A., Lose, F.A., Parsons, M.T., Walters, R.J., Pearson, S.A., 
Cummings, M., Oehler, M.K., Blomfield, P.B., Quinn, M.A., Kirk, J.A., Stewart, C.J., 
Obermair, A., Young, J.P., Webb, P.M., Spurdle, A.B., Tumor mismatch repair 
immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial 
cancer diagnosed at age younger than 60 years optimizes triage for population-level 





          [31]  Moline, J., Mahdi, H., Yang, B., Biscotti, C., Roma, A.A., Heald, B., Rose, P.G., Michener, C., 
Eng, C., Implementation of tumor testing for lynch syndrome in endometrial cancers at a 
large academic medical center, Gynecol.Oncol. 130 (2013) 121-126 
          [32]  Peltomaki, P., Epigenetic mechanisms in the pathogenesis of Lynch syndrome, Clin.Genet. 
85 (2014) 403-412 
          [33]  Meyer, L.A., Broaddus, R.R., Lu, K.H., Endometrial cancer and Lynch syndrome: clinical and 
pathologic considerations, Cancer Control. 16 (2009) 14-22 
          [34]  Committee opinion no. 634: Hereditary cancer syndromes and risk assessment, 
Obstet.Gynecol. 125 (2015) 1538-1543 
          [35]  WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): 
International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 
5th ed.; vol. 4). 
          [36]  Russo, M., Broach, J., Sheldon, K., Houser, K.R., Liu, D.J., Kesterson, J., Phaeton, R., Hossler, 
C., Hempel, N., Baker, M., Newell, J.M., Zaino, R., Warrick, J.I., Clonal evolution in paired 
endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid 
adenocarcinoma, Human Pathology. 67 (2017) 69-77.  
          [37]  Mutter, G.L., Lin, M.C., Fitzgerald, J.T., Kum, J.B., Baak, J.P., Lees, J.A., Weng, L.P., Eng, C., 
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers, 
J.Natl.Cancer Inst. 92 (2000) 924-930 
          [38]  Ayhan, A., Mao, T.L., Suryo Rahmanto, Y., Zeppernick, F., Ogawa, H., Wu, R.C., Wang, T.L., 
Shih, I., Increased proliferation in atypical hyperplasia/endometrioid intraepithelial 
neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour 
suppressors, J.Pathol.Clin.Res. 1 (2015) 186-193 
          [39]  Hayes, M.P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G.J., Baker, S.J., Ellenson, 
L.H., PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical 
hyperplasia, Clin.Cancer Res. 12 (2006) 5932-5935 
          [40]  Sun, H., Enomoto, T., Shroyer, K.R., Ozaki, K., Fujita, M., Ueda, Y., Nakashima, R., Kuragaki, 
C., Ueda, G., Murata, Y., Clonal analysis and mutations in the PTEN and the K-ras genes in 
endometrial hyperplasia, Diagn.Mol.Pathol. 11 (2002) 204-211 
          [41]  Bokhman, J.V., Two pathogenetic types of endometrial carcinoma, Gynecol.Oncol. 15 
(1983) 10-17 
          [42]  Mackay, H.J., Gallinger, S., Tsao, M.S., McLachlin, C.M., Tu, D., Keiser, K., Eisenhauer, E.A., 
Oza, A.M., Prognostic value of microsatellite instability (MSI) and PTEN expression in 
women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group 
(NCIC CTG), European Journal of Cancer. 46 (2010) 1365-1373.  
                       REFERENCES 
51 
 
          [43]  Nout, R.A., Bosse, T., Creutzberg, C.L., Jürgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, 
L.C.H.W., van der Steen-Banasik, E.M., van Eijk, R., ter Haar, N.T., Smit, V.T.H.B.M., 
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, 
Wnt/β-catenin and P53 pathway activation, Gynecol.Oncol. 126 (2012) 466-473 
          [44]  Byron, S.A., Gartside, M., Powell, M.A., Wellens, C.L., Gao, F., Mutch, D.G., Goodfellow, 
P.J., Pollock, P.M., FGFR2 point mutations in 466 endometrioid endometrial tumors: 
relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features, 
PLoS One. 7 (2012) e30801 
          [45]  Guan, B., Mao, T.L., Panuganti, P.K., Kuhn, E., Kurman, R.J., Maeda, D., Chen, E., Jeng, Y.M., 
Wang, T.L., Shih, I., Mutation and loss of expression of ARID1A in uterine low-grade 
endometrioid carcinoma , Am.J.Surg.Pathol. 35 (2011) 625-632 
          [46]  Wiegand, K.C., Lee, A.F., Al-Agha, O.M., Chow, C., Kalloger, S.E., Scott, D.W., Steidl, C., 
Wiseman, S.M., Gascoyne, R.D., Gilks, B., Huntsman, D.G., Loss of BAF250a (ARID1A) is 
frequent in high-grade endometrial carcinomas, J.Pathol. 224 (2011) 328-333 
          [47]  Esteller, M., Levine, R., Baylin, S.B., Ellenson, L.H., Herman, J.G., MLH1 promoter 
hypermethylation is associated with the microsatellite instability phenotype in sporadic 
endometrial carcinomas, Oncogene. 17 (1998) 2413-2417 
          [48]  Simpkins, S.B., Bocker, T., Swisher, E.M., Mutch, D.G., Gersell, D.J., Kovatich, A.J., Palazzo, 
J.P., Fishel, R., Goodfellow, P.J., MLH1 promoter methylation and gene silencing is the 
primary cause of microsatellite instability in sporadic endometrial cancers , 
Hum.Mol.Genet. 8 (1999) 661-666 
          [49]  Buchanan, D.D., Rosty, C., Clendenning, M., Spurdle, A.B., Win, A.K., Clinical problems of 
colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch 
repair deficiency (suspected Lynch syndrome), Appl.Clin.Genet. 7 (2014) 183-193 
          [50]  Geurts-Giele, W.R., Leenen, C.H., Dubbink, H.J., Meijssen, I.C., Post, E., Sleddens, H.F., 
Kuipers, E.J., Goverde, A., van den Ouweland, A.M., van Lier, M.G., Steyerberg, E.W., van 
Leerdam, M.E., Wagner, A., Dinjens, W.N., Somatic aberrations of mismatch repair genes 
as a cause of microsatellite-unstable cancers, J.Pathol. 234 (2014) 548-559 
          [51]  Xicola, R.M., Clark, J.R., Carroll, T., Alvikas, J., Marwaha, P., Regan, M.R., Lopez-Giraldez, F., 
Choi, J., Emmadi, R., Alagiozian-Angelova, V., Kupfer, S.S., Ellis, N.A., Llor, X., Implication of 
DNA repair genes in Lynch-like syndrome, Fam.Cancer. 18 (2019) 331-342 
          [52]  Haraldsdottir, S., Hampel, H., Tomsic, J., Frankel, W.L., Pearlman, R., de la Chapelle, A., 
Pritchard, C.C., Colon and endometrial cancers with mismatch repair deficiency can arise 
from somatic, rather than germline, mutations , Gastroenterology. 147 (2014) 1308-
1316.e1 
          [53]  Bosse, T., ter Haar, N.T., Seeber, L.M., v Diest, P.J., Hes, F.J., Vasen, H.F., Nout, R.A., 





with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial 
cancer , Mod.Pathol. 26 (2013) 1525-1535 
          [54]  Lagarda, H., Catasus, L., Arguelles, R., Matias-Guiu, X., Prat, J., K-ras mutations in 
endometrial carcinomas with microsatellite instability, J.Pathol. 193 (2001) 193-199 
          [55]  Machin, P., Catasus, L., Pons, C., Muñoz, J., Matias-Guiu, X., Prat, J., CTNNB1 mutations and 
β-catenin expression in endometrial carcinomas, Human Pathology. 33 (2002) 206-212. 
          [56]  Bansal, N., Yendluri, V., Wenham, R.M., The molecular biology of endometrial cancers and 
the implications for pathogenesis, classification, and targeted therapies , Cancer Control. 
16 (2009) 8-13 
          [57]  Alvarez, T., Miller, E., Duska, L., Oliva, E., Molecular profile of grade 3 endometrioid 
endometrial carcinoma: is it a type I or type II endometrial carcinoma?, Am.J.Surg.Pathol. 
36 (2012) 753-761 
          [58]  Schultheis, A.M., Martelotto, L.G., De Filippo, M.R., Piscuglio, S., Ng, C.K., Hussein, Y.R., 
Reis-Filho, J.S., Soslow, R.A., Weigelt, B., TP53 Mutational Spectrum in Endometrioid and 
Serous Endometrial Cancers, Int.J.Gynecol.Pathol. 35 (2016) 289-300 
          [59]  Han, G., Sidhu, D., Duggan, M.A., Arseneau, J., Cesari, M., Clement, P.B., Ewanowich, C.A., 
Kalloger, S.E., Kobel, M., Reproducibility of histological cell type in high-grade endometrial 
carcinoma, Mod.Pathol. 26 (2013) 1594-1604 
          [60]  Bae, H.S., Kim, H., Young Kwon, S., Kim, K.R., Song, J.Y., Kim, I., Should endometrial clear 
cell carcinoma be classified as Type II endometrial carcinoma? , Int.J.Gynecol.Pathol. 34 
(2015) 74-84 
          [61]  Gilks, C.B., Oliva, E., Soslow, R.A., Poor interobserver reproducibility in the diagnosis of 
high-grade endometrial carcinoma, Am.J.Surg.Pathol. 37 (2013) 874-881 
          [62]  Stelloo, E., Bosse, T., Nout, R.A., MacKay, H.J., Church, D.N., Nijman, H.W., Leary, A., 
Edmondson, R.J., Powell, M.E., Crosbie, E.J., Kitchener, H.C., Mileshkin, L., Pollock, P.M., 
Smit, V.T., Creutzberg, C.L., Refining prognosis and identifying targetable pathways for 
high-risk endometrial cancer; a TransPORTEC initiative, Modern Pathology. 28 (2015) 836-
844 
          [63]  Talhouk, A., McConechy, M.K., Leung, S., Li-Chang, H.H., Kwon, J.S., Melnyk, N., Yang, W., 
Senz, J., Boyd, N., Karnezis, A.N., Huntsman, D.G., Gilks, C.B., McAlpine, J.N., A clinically 
applicable molecular-based classification for endometrial cancers, Br.J.Cancer. 113 (2015) 
299-310 
          [64]  Raffone, A., Travaglino, A., Mascolo, M., Carotenuto, C., Guida, M., Mollo, A., Insabato, L., 
Zullo, F., Histopathological characterization of ProMisE molecular groups of endometrial 
cancer, Gynecologic Oncology 157 (2020) 252-259 
                       REFERENCES 
53 
 
          [65]  Cosgrove, C.M., Cohn, D.E., Goodfellow, P.J., Primum non nocere: Are we ready for POLE 
testing in endometrial cancer?, Gynecologic Oncology 147 (2017) 240-242 
          [66]  Veneris, J.T., Lee, E.K., Goebel, E.A., Nucci, M.R., Lindeman, N., Horowitz, N.S., Lee, L., Raut, 
C.P., Crotzer, D., Matulonis, U., Konstantinopoulos, P.A., Campos, S., Diagnosis and 
management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer, 
Gynecol.Oncol. 153 (2019) 471-478 
          [67]  Cosgrove, C.M., Cohn, D.E., Hampel, H., Frankel, W.L., Jones, D., McElroy, J.P., Suarez, A.A., 
Zhao, W., Chen, W., Salani, R., Copeland, L.J., O'Malley, D.M., Fowler, J.M., Yilmaz, A., 
Chassen, A.S., Pearlman, R., Goodfellow, P.J., Backes, F.J., Epigenetic silencing of MLH1 in 
endometrial cancers is associated with larger tumor volume, increased rate of lymph node 
positivity and reduced recurrence-free survival, Gynecologic Oncology. 146 (2017) 588-595 
          [68]  McMeekin, D.S., Tritchler, D.L., Cohn, D.E., Mutch, D.G., Lankes, H.A., Geller, M.A., Powell, 
M.A., Backes, F.J., Landrum, L.M., Zaino, R., Broaddus, R.D., Ramirez, N., Gao, F., Ali, S., 
Darcy, K.M., Pearl, M.L., DiSilvestro, P.A., Lele, S.B., Goodfellow, P.J., Clinicopathologic 
Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG 
Oncology/Gynecologic Oncology Group Study , J.Clin.Oncol. 34 (2016) 3062-3068 
          [69]  An, H.J., Kim, K.I., Kim, J.Y., Shim, J.Y., Kang, H., Kim, T.H., Kim, J.K., Jeong, J.K., Lee, S.Y., 
Kim, S.J., Microsatellite instability in endometrioid type endometrial adenocarcinoma is 
associated with poor prognostic indicators, Am.J.Surg.Pathol. 31 (2007) 846-853 
          [70]  Black, D., Soslow, R.A., Levine, D.A., Tornos, C., Chen, S.C., Hummer, A.J., Bogomolniy, F., 
Olvera, N., Barakat, R.R., Boyd, J., Clinicopathologic significance of defective DNA mismatch 
repair in endometrial carcinoma, J.Clin.Oncol. 24 (2006) 1745-1753 
          [71]  Guastadisegni, C., Colafranceschi, M., Ottini, L., Dogliotti, E., Microsatellite instability as a 
marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival 
data, Eur.J.Cancer. 46 (2010) 2788-2798 
          [72]  Popat, S., Hubner, R., Houlston, R.S., Systematic review of microsatellite instability and 
colorectal cancer prognosis, J.Clin.Oncol. 23 (2005) 609-618 
          [73]  Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., 
Luber, B.S., Azad, N.S., Laheru, D., Biedrzycki, B., Donehower, R.C., Zaheer, A., Fisher, G.A., 
Crocenzi, T.S., Lee, J.J., Duffy, S.M., Goldberg, R.M., de la Chapelle, A., Koshiji, M., Bhaijee, 
F., Huebner, T., Hruban, R.H., Wood, L.D., Cuka, N., Pardoll, D.M., Papadopoulos, N., 
Kinzler, K.W., Zhou, S., Cornish, T.C., Taube, J.M., Anders, R.A., Eshleman, J.R., Vogelstein, 
B., Diaz, L.A.,Jr, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency , N.Engl.J.Med. 
372 (2015) 2509-2520 
          [74]  Konstantinopoulos, P.A., Luo, W., Liu, J.F., Gulhan, D.C., Krasner, C., Ishizuka, J.J., Gockley, 
A.A., Buss, M., Growdon, W.B., Crowe, H., Campos, S., Lindeman, N.I., Hill, S., Stover, E., 
Schumer, S., Wright, A.A., Curtis, J., Quinn, R., Whalen, C., Gray, K.P., Penson, R.T., 





Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent 
Endometrial Cancer, J.Clin.Oncol. 37 (2019) 2786-2794 
          [75]  Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.P., 
Geva, R., Gottfried, M., Penel, N., Hansen, A.R., Piha-Paul, S.A., Doi, T., Gao, B., Chung, H.C., 
Lopez-Martin, J., Bang, Y.J., Frommer, R.S., Shah, M., Ghori, R., Joe, A.K., Pruitt, S.K., Diaz, 
L.A.,Jr, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite 
Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 
Study, J.Clin.Oncol. 38 (2020) 1-10 
          [76]  Fader, A.N., Diaz, L.A., Armstrong, D.K., Tanner, E.J., Uram, J., Eyring, A., Wang, H., Fisher, 
G., Greten, T., Le, D., Preliminary results of a phase II study: PD-1 blockade in mismatch 
repair–deficient, recurrent or persistent endometrial cancer, Gynecologic Oncology. 141 
(2016) 206-207 
          [77]  Reijnen, C., Kusters-Vandevelde, H.V.N., Prinsen, C.F., Massuger, L.F.A.G., Snijders, 
M.P.M.L., Kommoss, S., Brucker, S.Y., Kwon, J.S., McAlpine, J.N., Pijnenborg, J.M.A., 
Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in 
endometrial cancer, Gynecol.Oncol. 154 (2019) 124-130 
           [78]  Loukovaara, M., Pasanen, A., & Butzow, R. Mismatch repair protein and MLH1 methylation 
status as predictors of response to adjuvant therapy in endometrial cancer. Cancer 
Medicine. 10 (2021) 1034-1042 
          [79]  Stelloo, E., Nout, R.A., Osse, E.M., Jurgenliemk-Schulz, I.J., Jobsen, J.J., Lutgens, L.C., van 
der Steen-Banasik, E.M., Nijman, H.W., Putter, H., Bosse, T., Creutzberg, C.L., Smit, V.T., 
Improved risk assessment by integrating molecular and clinicopathological factors in early-
stage endometrial cancer - combined analysis of PORTEC cohorts, Clin.Cancer Res. 22 
(2016) 4215-24 
           [80]  Kommoss, S., McConechy, M.K., Kommoss, F., Leung, S., Bunz, A., Magrill, J., Britton, H., 
Kommoss, F., Grevenkamp, F., Karnezis, A., Yang, W., Lum, A., Kramer, B., Taran, F., 
Staebler, A., Lax, S., Brucker, S.Y., Huntsman, D.G., Gilks, C.B., McAlpine, J.N., Talhouk, A., 
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large 
population-based case series, Ann.Oncol. 29 (2018) 1180-1188 
          [81]  Raffone, A., Travaglino, A., Mascolo, M., Carbone, L., Guida, M., Insabato, L., Zullo, F., TCGA 
molecular groups of endometrial cancer: Pooled data about prognosis, Gynecol.Oncol. 155 
(2019) 374-383 
          [82]  Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., 
Marth, C., Nout, R., Querleu, D., Mirza, M.R., Sessa, C., ESMO-ESGO-ESTRO Endometrial 
Consensus Conference Working Group, ESMO-ESGO-ESTRO Consensus Conference on 
Endometrial Cancer: diagnosis, treatment and follow-updagger, Ann.Oncol. 27 (2016) 16-
41 
                       REFERENCES 
55 
 
          [83]  Bogani, G., Dowdy, S.C., Cliby, W.A., Ghezzi, F., Rossetti, D., Mariani, A., Role of pelvic and 
para-aortic lymphadenectomy in endometrial cancer: current evidence, 
J.Obstet.Gynaecol.Res. 40 (2014) 301-311 
          [84]  Bogani, G., Ditto, A., Signorelli, M., Chiappa, V., Martinelli, F., Raspagliesi, F., Sentinel Node 
Mapping in Endometrial Cancer, J.Invest.Surg. (2019) 1-2 
          [85]  Shepherd, J.H., Revised FIGO staging for gynaecological cancer, Br.J.Obstet.Gynaecol. 96 
(1989) 889-892 
          [86]  Pecorelli, S., Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium, 
Int.J.Gynaecol.Obstet. 105 (2009) 103-104 
          [87]  Fife, B.T., Bluestone, J.A., Control of peripheral T-cell tolerance and autoimmunity via the 
CTLA-4 and PD-1 pathways, Immunol.Rev. 224 (2008) 166-182 
          [88]  Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., 
McDermott, D.F., Powderly, J.D., Gettinger, S.N., Kohrt, H.E., Horn, L., Lawrence, D.P., Rost, 
S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P.S., Mellman, I., Chen, D.S., 
Hodi, F.S., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in 
cancer patients, Nature. 515 (2014) 563-567 
          [89]  https://www.agilent.com/cs/library/usermanuals/public/29219_pd-l1-ihc-22C3-pharmdx-
gastric-interpretation-manual_us.pdf 
          [90]  http://www.ventana.com/documents/PD-L1_SP142-NSCLC-Brochure.pdf 
          [91]  http://www.ventana.com/documents/PD-L1_SP142-UC-Brochure.pdf 
          [92]  Brunnstrom, H., Johansson, A., Westbom-Fremer, S., Backman, M., Djureinovic, D., 
Patthey, A., Isaksson-Mettavainio, M., Gulyas, M., Micke, P., PD-L1 immunohistochemistry 
in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay 
variability, Mod.Pathol. 30 (2017) 1411-1421 
          [93]  Herzog, T., Arguello, D., Reddy, S.K., Gatalica, Z., PD-1, PD-L1 expression in 1599 
gynecological cancers: Implications for immunotherapy, Gynecologic Oncology. 137 (2015) 
204-205 
          [94]  Howitt, B.E., Shukla, S.A., Sholl, L.M., Ritterhouse, L.L., Watkins, J.C., Rodig, S., Stover, E., 
Strickland, K.C., D'Andrea, A.D., Wu, C.J., Matulonis, U.A., Konstantinopoulos, P.A., 
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers 
With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 
and PD-L1, JAMA Oncol. 1 (2015) 1319-1323 
          [95]  Eggink, F.A., Van Gool, I.C., Leary, A., Pollock, P.M., Crosbie, E.J., Mileshkin, L., Jordanova, 
E.S., Adam, J., Freeman-Mills, L., Church, D.N., Creutzberg, C.L., De Bruyn, M., Nijman, 





cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for 
checkpoint inhibition, Oncoimmunology. 6 (2016) e1264565 
          [96]  Mo, Z., Liu, J., Zhang, Q., Chen, Z., Mei, J., Liu, L., Yang, S., Li, H., Zhou, L., You, Z., 
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and 
histological type of endometrial cancer , Oncol.Lett. 12 (2016) 944-950 
          [97]  Bregar, A., Deshpande, A., Grange, C., Zi, T., Stall, J., Hirsch, H., Reeves, J., 
Sathyanarayanan, S., Growdon, W.B., Rueda, B.R., Characterization of immune regulatory 
molecules B7-H4 and PD-L1 in low and high grade endometrial tumors, Gynecol.Oncol. 145 
(2017) 446-452 
          [98] Yamashita, H., Nakayama, K., Ishikawa, M., Nakamura, K., Ishibashi, T., Sanuki, K., Ono, R., 
Sasamori, H., Minamoto, T., Iida, K., Sultana, R., Ishikawa, N., Kyo, S., Microsatellite 
instability is a biomarker for immune checkpoint inhibitors in endometrial cancer, 
Oncotarget. 9 (2017) 5652-5664 
          [99]  Sloan, E.A., Ring, K.L., Willis, B.C., Modesitt, S.C., Mills, A.M., PD-L1 Expression in Mismatch 
Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 
Promoter Hypermethylated Tumors , Am.J.Surg.Pathol. 41 (2017) 326-333 
          [100] Li, Z., Joehlin-Price, A.S., Rhoades, J., Ayoola-Adeola, M., Miller, K., Parwani, A.V., Backes, 
F.J., Felix, A.S., Suarez, A.A., Programmed Death Ligand 1 Expression Among 700 
Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein 
Deficiency, Int.J.Gynecol.Cancer. 28 (2018) 59-68 
        [101]  Kim, J., Kim, S., Lee, H.S., Yang, W., Cho, H., Chay, D.B., Cho, S.J., Hong, S., Kim, J.H., 
Prognostic implication of programmed cell death 1 protein and its ligand expressions in 
endometrial cancer , Gynecol.Oncol. 149 (2018) 381-387 
         [102]  Asaka, S., Yen, T.T., Wang, T.L., Shih, I.M., Gaillard, S., T cell-inflamed phenotype and 
increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial 
cancers, Mod.Pathol. 32 (2019) 576-584 
        [103]  Crumley, S., Kurnit, K., Hudgens, C., Fellman, B., Tetzlaff, M.T., Broaddus, R., Identification 
of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ 
lymphocytes , Mod.Pathol. 32 (2019) 396-404 
        [104]  Kucukgoz Gulec, U., Kilic Bagir, E., Paydas, S., Guzel, A.B., Gumurdulu, D., Vardar, M.A., 
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 
endometrial cancer, Arch.Gynecol.Obstet. 300 (2019)377-382 
        [105]  Talhouk, A., Derocher, H., Schmidt, P., Leung, S., Milne, K., Gilks, C.B., Anglesio, M.S., 
Nelson, B.H., McAlpine, J.N., Molecular Subtype Not Immune Response Drives Outcomes in 
Endometrial Carcinoma , Clin.Cancer Res. 25 (2019) 2537-2548 
                       REFERENCES 
57 
 
        [106] Pakish, J.B., Zhang, Q., Chen, Z., Liang, H., Chisholm, G.B., Yuan, Y., Mok, S.C., Broaddus, 
R.R., Lu, K.H., Yates, M.S., Immune Microenvironment in Microsatellite-Instable 
Endometrial Cancers: Hereditary or Sporadic Origin Matters, Clin.Cancer Res. 23 (2017) 
4473-4481 
         [107] Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, 
B., Spasic, M., Henry, G., Ciobanu, V., West, A.N., Carmona, M., Kivork, C., Seja, E., Cherry, 
G., Gutierrez, A.J., Grogan, T.R., Mateus, C., Tomasic, G., Glaspy, J.A., Emerson, R.O., 
Robins, H., Pierce, R.H., Elashoff, D.A., Robert, C., Ribas, A., PD-1 blockade induces 
responses by inhibiting adaptive immune resistance , Nature. 515 (2014) 568-571 
        [108]  Teng, M.W., Ngiow, S.F., Ribas, A., Smyth, M.J., Classifying Cancers Based on T-cell 
Infiltration and PD-L1, Cancer Res. 75 (2015) 2139-2145 
        [109]  Althammer, S., Tan, T.H., Spitzmuller, A., Rognoni, L., Wiestler, T., Herz, T., Widmaier, M., 
Rebelatto, M.C., Kaplon, H., Damotte, D., Alifano, M., Hammond, S.A., Dieu-Nosjean, M.C., 
Ranade, K., Schmidt, G., Higgs, B.W., Steele, K.E., Automated image analysis of NSCLC 
biopsies to predict response to anti-PD-L1 therapy, J.Immunother.Cancer. 7 (2019) 121-
019-0589-x 
         [110]  www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm 
        [111]  Talhouk, A., McConechy, M.K., Leung, S., Yang, W., Lum, A., Senz, J., Boyd, N., Pike, J., 
Anglesio, M., Kwon, J.S., Karnezis, A.N., Huntsman, D.G., Gilks, C.B., McAlpine, J.N., 
Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial 
cancer, Cancer. 123 (2017) 802-813 
        [112]  Weinspach, D., Seubert, B., Schaten, S., Honert, K., Sebens, S., Altevogt, P., Kruger, A., Role 
of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of 
dissemination, colonization, and metastatic growth, Clin.Exp.Metastasis. 31 (2014) 87-100 
        [113] Altevogt, P., Doberstein, K., Fogel, M., L1CAM in human cancer, Int.J.Cancer 138 (2015) 
1565-76 
        [114]  Zeimet, A.G., Reimer, D., Huszar, M., Winterhoff, B., Puistola, U., Azim, S.A., Muller-
Holzner, E., Ben-Arie, A., van Kempen, L.C., Petru, E., Jahn, S., Geels, Y.P., Massuger, L.F., 
Amant, F., Polterauer, S., Lappi-Blanco, E., Bulten, J., Meuter, A., Tanouye, S., Oppelt, P., 
Stroh-Weigert, M., Reinthaller, A., Mariani, A., Hackl, W., Netzer, M., Schirmer, U., Vergote, 
I., Altevogt, P., Marth, C., Fogel, M., L1CAM in early-stage type I endometrial cancer: 
results of a large multicenter evaluation, J.Natl.Cancer Inst. 105 (2013) 1142-1150 
        [115]  Bosse, T., Nout, R.A., Stelloo, E., Dreef, E., Nijman, H.W., Jürgenliemk-Schulz, I.M., Jobsen, 
J.J., Creutzberg, C.L., Smit, V.T.H.B.M., L1 cell adhesion molecule is a strong predictor for 
distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC 





        [116]  Dellinger, T.H., Smith, D.D., Ouyang, C., Warden, C.D., Williams, J.C., Han, E.S., L1CAM is an 
independent predictor of poor survival in endometrial cancer - An analysis of The Cancer 
Genome Atlas (TCGA), Gynecol.Oncol. 141 (2016) 336-340 
        [117]  van der Putten, L.J., Visser, N.C., van de Vijver, K., Santacana, M., Bronsert, P., Bulten, J., 
Hirschfeld, M., Colas, E., Gil-Moreno, A., Garcia, A., Mancebo, G., Alameda, F., Trovik, J., 
Kopperud, R.K., Huvila, J., Schrauwen, S., Koskas, M., Walker, F., Weinberger, V., Minar, L., 
Jandakova, E., Snijders, M.P., van den Berg-van Erp, S., Matias-Guiu, X., Salvesen, H.B., 
Amant, F., Massuger, L.F., Pijnenborg, J.M., L1CAM expression in endometrial carcinomas: 
an ENITEC collaboration study , Br.J.Cancer 115 (2016)716-24 
        [118]  van der Putten, L.J.M., Visser, N.C.M., van de Vijver, K., Santacana, M., Bronsert, P., Bulten, 
J., Hirschfeld, M., Colas, E., Gil-Moreno, A., Garcia, A., Mancebo, G., Alameda, F., Trovik, J., 
Kopperud, R.K., Huvila, J., Schrauwen, S., Koskas, M., Walker, F., Weinberger, V., Minar, L., 
Jandakova, E., Snijders, M.P.L.M., van den Berg-van Erp, S., Matias-Guiu, X., Salvesen, H.B., 
Werner, H.M.J., Amant, F., Massuger, L.F.A.G., Pijnenborg, J.M.A., Added Value of Estrogen 
Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-
Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration 
Study, Int.J.Gynecol.Cancer. 28 (2018) 514-523 
        [119]  Huvila, J., Talve, L., Carpen, O., Edqvist, P.H., Ponten, F., Grenman, S., Auranen, A., 
Progesterone receptor negativity is an independent risk factor for relapse in patients with 
early stage endometrioid endometrial adenocarcinoma, Gynecol.Oncol. 130 (2013) 463-
469  
        [120]  Edqvist, P.H., Huvila, J., Forsstrom, B., Talve, L., Carpen, O., Salvesen, H.B., Krakstad, C., 
Grenman, S., Johannesson, H., Ljungqvist, O., Uhlen, M., Ponten, F., Auranen, A., Loss of 
ASRGL1 expression is an independent biomarker for disease-specific survival in 
endometrioid endometrial carcinoma, Gynecol.Oncol. 137 (2015) 529-537 
        [121]  Wik, E., Birkeland, E., Trovik, J., Werner, H.M., Hoivik, E.A., Mjos, S., Krakstad, C., 
Kusonmano, K., Mauland, K., Stefansson, I.M., Holst, F., Petersen, K., Oyan, A.M., Simon, R., 
Kalland, K.H., Ricketts, W., Akslen, L.A., Salvesen, H.B., High phospho-Stathmin(Serine38) 
expression identifies aggressive endometrial cancer and suggests an association with PI3K 
inhibition, Clin.Cancer Res. 19 (2013) 2331-2341 
        [122]  Creasman, W.T., Prognostic significance of hormone receptors in endometrial cancer, 
Cancer. 71 (1993) 1467-1470 
        [123]  Di Donato, V., Iacobelli, V., Schiavi, M.C., Colagiovanni, V., Pecorella, I., Palaia, I., Perniola, 
G., Marchetti, C., Musella, A., Tomao, F., Monti, M., Muzii, L., Benedetti Panici, P., Impact 
of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients 
Affected by High-risk Endometrial Cancer , Int.J.Gynecol.Cancer. 28 (2018) 505-513 
        [124]  Matias-Guiu, X., Davidson, B., Prognostic biomarkers in endometrial and ovarian 
carcinoma, Virchows Arch. 464 (2014) 315-331 
                       REFERENCES 
59 
 
         [125] Landis, J. R., & Koch, G. G. The measurement of observer agreement for categorical data.   
Biometrics, 33 (1977) 159-174. 
         [126]  Talhouk, A., Hoang, L.N., McConechy, M.K., Nakonechny, Q., Leo, J., Cheng, A., Leung, S., 
Yang, W., Lum, A., Köbel, M., Lee, C., Soslow, R.A., Huntsman, D.G., Gilks, C.B., McAlpine, 
J.N., Molecular classification of endometrial carcinoma on diagnostic specimens is highly 
concordant with final hysterectomy: Earlier prognostic information to guide treatment, 
Gynecol.Oncol. 143 (2016) 46-53 
        [127]  Tangen, I.L., Kopperud, R.K., Visser, N.C., Staff, A.C., Tingulstad, S., Marcickiewicz, J., 
Amant, F., Bjorge, L., Pijnenborg, J.M., Salvesen, H.B., Werner, H.M., Trovik, J., Krakstad, C., 
Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples 
predicts lymph node metastases and poor outcome in endometrial cancer patients, 
Br.J.Cancer. 117 (2017) 840-847 
        [128]  Guan, H., Semaan, A., Bandyopadhyay, S., Arabi, H., Feng, J., Fathallah, L., Pansare, V., Qazi, 
A., Abdul-Karim, F., Morris, R.T., Munkarah, A.R., Ali-Fehmi, R., Prognosis and 
reproducibility of new and existing binary grading systems for endometrial carcinoma 
compared to FIGO grading in hysterectomy specimens , Int.J.Gynecol.Cancer. 21 (2011) 
654-660 
        [129]  Wortman, B.G., Bosse, T., Nout, R.A., Lutgens, L.C.H.W., van der Steen-Banasik, E.M., 
Westerveld, H., van den Berg, H., Slot, A., De Winter, K.A.J., Verhoeven-Adema, K.W., Smit, 
V.T.H.B.M., Creutzberg, C.L., PORTEC Study Group, Molecular-integrated risk profile to 
determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of 
the PORTEC-4a trial, Gynecol.Oncol. 151 (2018) 69-75 
        [130]  Maten, M.V., Reijnen, C., Pijnenborg, J.M.A., Zegers, M.M., L1 Cell Adhesion Molecule in 
Cancer, a Systematic Review on Domain-Specific Functions, Int.J.Mol.Sci. 20 (2019) 4180 
        [131]  Fogel, M., Gutwein, P., Mechtersheimer, S., Riedle, S., Stoeck, A., Smirnov, A., Edler, L., 
Ben-Arie, A., Huszar, M., Altevogt, P., L1 expression as a predictor of progression and 
survival in patients with uterine and ovarian carcinomas, Lancet. 362 (2003) 869-875 
        [132]  Auguste, A., Genestie, C., De Bruyn, M., Adam, J., Le Formal, A., Drusch, F., Pautier, P., 
Crosbie, E.J., MacKay, H., Kitchener, H.C., Powell, M., Pollock, P.M., Mileshkin, L., 
Edmondson, R.J., Nout, R., Nijman, H.W., Creutzberg, C.L., Bosse, T., Leary, A., Refinement 
of high-risk endometrial cancer classification using DNA damage response biomarkers: a 
TransPORTEC initiative, Mod.Pathol. 31 (2018) 1851-1861 
        [133]  Leon-Castillo, A., de Boer, S.M., Powell, M.E., Mileshkin, L.R., Mackay, H.J., Leary, A., 
Nijman, H.W., Singh, N., Pollock, P.M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, 
V.T.H.B.M., Edmondson, R.J., Putter, H., Kitchener, H.C., Crosbie, E.J., de Bruyn, M., Nout, 
R.A., Horeweg, N., Creutzberg, C.L., Bosse, T., TransPORTEC consortium, Molecular 
Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis 





        [134]  Cosgrove, C.M., Tritchler, D.L., Cohn, D.E., Mutch, D.G., Rush, C.M., Lankes, H.A., 
Creasman, W.T., Miller, D.S., Ramirez, N.C., Geller, M.A., Powell, M.A., Backes, F.J., 
Landrum, L.M., Timmers, C., Suarez, A.A., Zaino, R.J., Pearl, M.L., DiSilvestro, P.A., Lele, S.B., 
Goodfellow, P.J., An NRG Oncology/GOG study of molecular classification for risk 
prediction in endometrioid endometrial cancer , Gynecol.Oncol. 148 (2018) 174-180 
        [135] Rambau, P. F., Vierkant, R. A., Intermaggio, M. P., Kelemen, L. E., Goodman, M. T., Herpel, 
E., et al. (2018). Association of p16 expression with prognosis varies across ovarian 
carcinoma histotypes: An ovarian tumor tissue analysis consortium study. The Journal of 
Pathology.Clinical Research, 4(4), 250-261. 
        [136]  Weisenberger, D.J., Siegmund, K.D., Campan, M., Young, J., Long, T.I., Faasse, M.A., Kang, 
G.H., Widschwendter, M., Weener, D., Buchanan, D., Koh, H., Simms, L., Barker, M., 
Leggett, B., Levine, J., Kim, M., French, A.J., Thibodeau, S.N., Jass, J., Haile, R., Laird, P.W., 
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly 
associated with BRAF mutation in colorectal cancer, Nat.Genet. 38 (2006) 787-793 
        [137]  Jass, J.R., HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological 
similarities and differences, Fam.Cancer. 3 (2004) 93-100 
        [138]  Porkka, N., Lahtinen, L., Ahtiainen, M., Böhm, J.P., Kuopio, T., Eldfors, S., Mecklin, J., 
Seppälä, T.T., Peltomäki, P., Epidemiological, clinical and molecular characterization of 
Lynch-like syndrome: A population-based study, Int.J.Cancer. 145 (2019) 87-98 
        [139]  Haraldsdottir, S., Hampel, H., Wu, C., Weng, D.Y., Shields, P.G., Frankel, W.L., Pan, X., de la 
Chapelle, A., Goldberg, R.M., Bekaii-Saab, T., Patients with colorectal cancer associated 
with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses, 
Genet.Med. 18 (2016) 863-868 
        [140]  Cohen, R., Buhard, O., Cervera, P., Hain, E., Dumont, S., Bardier, A., Bachet, J.B., Gornet, 
J.M., Lopez-Trabada, D., Dumont, S., Kaci, R., Bertheau, P., Renaud, F., Bibeau, F., Parc, Y., 
Vernerey, D., Duval, A., Svrcek, M., Andre, T., Clinical and molecular characterisation of 
hereditary and sporadic metastatic colorectal cancers harbouring microsatellite 
instability/DNA mismatch repair deficiency, Eur.J.Cancer. 86 (2017) 266-274 
        [141]  Chavez, J.A., Wei, L., Suarez, A.A., Parwani, A.V., Li, Z., Clinicopathologic characteristics, 
tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 
endometrial carcinomas with deficient mismatch repair function, Int.J.Gynecol.Cancer. 29 
(2019) 113-118 
        [142]  Ott, P.A., Bang, Y.J., Berton-Rigaud, D., Elez, E., Pishvaian, M.J., Rugo, H.S., Puzanov, I., 
Mehnert, J.M., Aung, K.L., Lopez, J., Carrigan, M., Saraf, S., Chen, M., Soria, J.C., Safety and 
Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive 
Endometrial Cancer: Results From the KEYNOTE-028 Study , J.Clin.Oncol. 35 (2017) 2535-
2541 
                       REFERENCES 
61 
 
        [143]  Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, 
H., Wilt, C., Luber, B.S., Wong, F., Azad, N.S., Rucki, A.A., Laheru, D., Donehower, R., 
Zaheer, A., Fisher, G.A., Crocenzi, T.S., Lee, J.J., Greten, T.F., Duffy, A.G., Ciombor, K.K., 
Eyring, A.D., Lam, B.H., Joe, A., Kang, S.P., Holdhoff, M., Danilova, L., Cope, L., Meyer, C., 
Zhou, S., Goldberg, R.M., Armstrong, D.K., Bever, K.M., Fader, A.N., Taube, J., Housseau, F., 
Spetzler, D., Xiao, N., Pardoll, D.M., Papadopoulos, N., Kinzler, K.W., Eshleman, J.R., 
Vogelstein, B., Anders, R.A., Diaz, L.A.,Jr, Mismatch repair deficiency predicts response of 
solid tumors to PD-1 blockade, Science. 357 (2017) 409-413 
        [144]  Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, 
E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M.A., Fayette, J., 
Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crino, L., 
Blumenschein, G.R.,Jr, Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., 
Brahmer, J.R., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung 
Cancer , N.Engl.J.Med. 373 (2015) 1627-1639 
        [145]  Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., Molina, J., Kim, J.H., 
Arvis, C.D., Ahn, M.J., Majem, M., Fidler, M.J., de Castro, G.,Jr, Garrido, M., Lubiniecki, 
G.M., Shentu, Y., Im, E., Dolled-Filhart, M., Garon, E.B., Pembrolizumab versus docetaxel 
for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): 
a randomised controlled trial, Lancet. 387 (2016) 1540-1550 
        [146]  McLaughlin, J., Han, G., Schalper, K.A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., 
Velcheti, V., Herbst, R., LoRusso, P., Rimm, D.L., Quantitative Assessment of the 
Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer, JAMA Oncol. 2 (2016) 
46-54 
        [147]  Hirsch, F.R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., 
Richardson, W., Towne, P., Hanks, D., Vennapusa, B., Mistry, A., Kalamegham, R., 
Averbuch, S., Novotny, J., Rubin, E., Emancipator, K., McCaffery, I., Williams, J.A., Walker, 
J., Longshore, J., Tsao, M.S., Kerr, K.M., PD-L1 Immunohistochemistry Assays for Lung 
Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project , 
J.Thorac.Oncol. 12 (2017) 208-222 
        [148]  Lewin, S.N., Herzog, T.J., Barrena Medel, N.I., Deutsch, I., Burke, W.M., Sun, X., Wright, J.D., 
Comparative performance of the 2009 international Federation of gynecology and 
obstetrics' staging system for uterine corpus cancer , Obstet.Gynecol. 116 (2010) 1141-
1149 
        [149]  Creasman, W.T., Ali, S., Mutch, D.G., Zaino, R.J., Powell, M.A., Mannel, R.S., Backes, F.J., 
DiSilvestro, P.A., Argenta, P.A., Pearl, M.L., Lele, S.B., Guntupalli, S.R., Waggoner, S., 
Spirtos, N., Boggess, J.F., Edwards, R.P., Filiaci, V.L., Miller, D.S., Surgical-pathological 
findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology 
Group study on GOG-210 protocol, Gynecol.Oncol. 145 (2017) 519-525 
        [150]  Keys, H.M., Roberts, J.A., Brunetto, V.L., Zaino, R.J., Spirtos, N.M., Bloss, J.D., Pearlman, A., 





external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a 
Gynecologic Oncology Group study", Gynecol.Oncol. 92 (2004) 744-751 
        [151]  Visser, N.C.M., van der Wurff, A.A.M., Pijnenborg, J.M.A., Massuger, L.F.A.G., Bulten, J., 
Nagtegaal, I.D., Tissue microarray is suitable for scientific biomarkers studies in 
endometrial cancer, Virchows Arch. 472 (2018) 407-413 
        [152]  Fons, G., Hasibuan, S.M., van der Velden, J., ten Kate, F.J., Validation of tissue microarray 
technology in endometrioid cancer of the endometrium, J.Clin.Pathol. 60 (2007) 500-503 
        [153]  Camp, R.L., Charette, L.A., Rimm, D.L., Validation of tissue microarray technology in breast 
carcinoma, Lab.Invest. 80 (2000) 1943-1949 
 
 
 
 
 
 
 
 
